US20230348521A1 - Methods of synthesizing nicotinamide riboside - Google Patents
Methods of synthesizing nicotinamide riboside Download PDFInfo
- Publication number
- US20230348521A1 US20230348521A1 US18/131,058 US202318131058A US2023348521A1 US 20230348521 A1 US20230348521 A1 US 20230348521A1 US 202318131058 A US202318131058 A US 202318131058A US 2023348521 A1 US2023348521 A1 US 2023348521A1
- Authority
- US
- United States
- Prior art keywords
- compound
- subject
- administering
- hcl
- sleep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 145
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 title abstract description 52
- 239000011618 nicotinamide riboside Substances 0.000 title abstract description 40
- 235000020956 nicotinamide riboside Nutrition 0.000 title abstract description 40
- 230000002194 synthesizing effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 127
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 117
- 150000001875 compounds Chemical class 0.000 claims description 89
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 75
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 56
- 239000002904 solvent Substances 0.000 claims description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- 230000001965 increasing effect Effects 0.000 claims description 36
- 239000012320 chlorinating reagent Substances 0.000 claims description 35
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 33
- 239000011541 reaction mixture Substances 0.000 claims description 32
- 210000003734 kidney Anatomy 0.000 claims description 31
- 229910021529 ammonia Inorganic materials 0.000 claims description 30
- 239000003153 chemical reaction reagent Substances 0.000 claims description 26
- 229940125782 compound 2 Drugs 0.000 claims description 25
- 229940126214 compound 3 Drugs 0.000 claims description 24
- 229940125904 compound 1 Drugs 0.000 claims description 20
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 19
- 208000033626 Renal failure acute Diseases 0.000 claims description 18
- 201000011040 acute kidney failure Diseases 0.000 claims description 18
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 claims description 16
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical group N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 claims description 16
- 230000006378 damage Effects 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 15
- 239000012465 retentate Substances 0.000 claims description 15
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 14
- 230000003247 decreasing effect Effects 0.000 claims description 14
- 206010022437 insomnia Diseases 0.000 claims description 14
- 208000005264 motor neuron disease Diseases 0.000 claims description 14
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 claims description 13
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 12
- 108010082126 Alanine transaminase Proteins 0.000 claims description 12
- 206010067125 Liver injury Diseases 0.000 claims description 11
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 11
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 10
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 10
- 231100000234 hepatic damage Toxicity 0.000 claims description 10
- 230000008818 liver damage Effects 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- 230000003860 sleep quality Effects 0.000 claims description 9
- 230000017531 blood circulation Effects 0.000 claims description 8
- 208000026072 Motor neurone disease Diseases 0.000 claims description 7
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 210000002161 motor neuron Anatomy 0.000 claims description 7
- 208000004930 Fatty Liver Diseases 0.000 claims description 6
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 6
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 6
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 6
- 208000010706 fatty liver disease Diseases 0.000 claims description 6
- 230000035558 fertility Effects 0.000 claims description 6
- 208000017169 kidney disease Diseases 0.000 claims description 6
- 230000006651 lactation Effects 0.000 claims description 6
- 230000016087 ovulation Effects 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 6
- 230000036512 infertility Effects 0.000 claims description 5
- 208000000509 infertility Diseases 0.000 claims description 5
- 231100000535 infertility Toxicity 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 206010056677 Nerve degeneration Diseases 0.000 claims description 3
- 230000004635 cellular health Effects 0.000 claims description 3
- -1 riboside triacetate Chemical class 0.000 abstract description 14
- 238000003786 synthesis reaction Methods 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 105
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
- 239000000047 product Substances 0.000 description 29
- 239000011570 nicotinamide Substances 0.000 description 26
- 235000005152 nicotinamide Nutrition 0.000 description 26
- 229960003966 nicotinamide Drugs 0.000 description 26
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 description 26
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 description 26
- 201000010099 disease Diseases 0.000 description 24
- 230000007958 sleep Effects 0.000 description 24
- 210000000287 oocyte Anatomy 0.000 description 20
- IHNHAHWGVLXCCI-FDYHWXHSSA-N [(2r,3r,4r,5s)-3,4,5-triacetyloxyoxolan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O IHNHAHWGVLXCCI-FDYHWXHSSA-N 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 18
- 235000019441 ethanol Nutrition 0.000 description 18
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 15
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 13
- 235000014113 dietary fatty acids Nutrition 0.000 description 13
- 239000000194 fatty acid Substances 0.000 description 13
- 229930195729 fatty acid Natural products 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 150000004665 fatty acids Chemical class 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 230000004720 fertilization Effects 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 230000004797 therapeutic response Effects 0.000 description 11
- 231100000331 toxic Toxicity 0.000 description 11
- 230000002588 toxic effect Effects 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000013589 supplement Substances 0.000 description 10
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 8
- 239000012346 acetyl chloride Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 210000000582 semen Anatomy 0.000 description 8
- 238000010189 synthetic method Methods 0.000 description 8
- 230000008733 trauma Effects 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- YABIFCKURFRPPO-IVOJBTPCSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide;chloride Chemical compound [Cl-].NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 YABIFCKURFRPPO-IVOJBTPCSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 208000023275 Autoimmune disease Diseases 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000027288 circadian rhythm Effects 0.000 description 6
- 239000013058 crude material Substances 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 208000002320 spinal muscular atrophy Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- 125000005270 trialkylamine group Chemical group 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 231100000268 induced nephrotoxicity Toxicity 0.000 description 5
- 230000001788 irregular Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 230000003442 weekly effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010019851 Hepatotoxicity Diseases 0.000 description 4
- 208000008852 Hyperoxaluria Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- IHNHAHWGVLXCCI-PFGBXZAXSA-N [(2r,3r,4r)-3,4,5-triacetyloxyoxolan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@H]1OC(OC(C)=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O IHNHAHWGVLXCCI-PFGBXZAXSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 231100000304 hepatotoxicity Toxicity 0.000 description 4
- 230000007686 hepatotoxicity Effects 0.000 description 4
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 201000010901 lateral sclerosis Diseases 0.000 description 4
- 206010025135 lupus erythematosus Diseases 0.000 description 4
- 230000007659 motor function Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000003880 polar aprotic solvent Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 201000002241 progressive bulbar palsy Diseases 0.000 description 4
- 201000008752 progressive muscular atrophy Diseases 0.000 description 4
- 239000003586 protic polar solvent Substances 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 208000019116 sleep disease Diseases 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- 210000001635 urinary tract Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010018364 Glomerulonephritis Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 230000009027 insemination Effects 0.000 description 3
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 208000013651 non-24-hour sleep-wake syndrome Diseases 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 230000008454 sleep-wake cycle Effects 0.000 description 3
- 208000020685 sleep-wake disease Diseases 0.000 description 3
- 230000019100 sperm motility Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000000153 supplemental effect Effects 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 230000002618 waking effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- OOCCDEMITAIZTP-QPJJXVBHSA-N (E)-cinnamyl alcohol Chemical compound OC\C=C\C1=CC=CC=C1 OOCCDEMITAIZTP-QPJJXVBHSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010001423 Advanced sleep phase Diseases 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012209 Delayed sleep phase Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010072268 Drug-induced liver injury Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241001669679 Eleotris Species 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- 208000018565 Hemochromatosis Diseases 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 206010022035 Initial insomnia Diseases 0.000 description 2
- 208000000913 Kidney Calculi Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010027439 Metal poisoning Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010029148 Nephrolithiasis Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 206010049226 Oxalosis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010051482 Prostatomegaly Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 206010038540 Renal tubular necrosis Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010041955 Stasis dermatitis Diseases 0.000 description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000018839 Wilson disease Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000036626 alertness Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 208000026900 bile duct neoplasm Diseases 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- PSBABBDEUFNFKJ-UHFFFAOYSA-N cyclopent-2-en-1-ol Chemical compound OC1CCC=C1 PSBABBDEUFNFKJ-UHFFFAOYSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 125000000532 dioxanyl group Chemical group 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 201000010284 hepatitis E Diseases 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 201000006334 interstitial nephritis Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000008127 lead poisoning Diseases 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 231100000845 liver adenoma Toxicity 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000008452 non REM sleep Effects 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 201000000196 pseudobulbar palsy Diseases 0.000 description 2
- OBLVPWTUALCMGD-UHFFFAOYSA-N pyridin-1-ium-3-carboxamide;chloride Chemical compound Cl.NC(=O)C1=CC=CN=C1 OBLVPWTUALCMGD-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 description 2
- 208000026775 severe diarrhea Diseases 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 230000021595 spermatogenesis Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WCASXYBKJHWFMY-NSCUHMNNSA-N 2-Buten-1-ol Chemical compound C\C=C\CO WCASXYBKJHWFMY-NSCUHMNNSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- ZVSCENGNXWPDPL-UHFFFAOYSA-N 2-methyl-2-phenylpropan-1-ol Chemical compound OCC(C)(C)C1=CC=CC=C1 ZVSCENGNXWPDPL-UHFFFAOYSA-N 0.000 description 1
- BYDRTKVGBRTTIT-UHFFFAOYSA-N 2-methylprop-2-en-1-ol Chemical compound CC(=C)CO BYDRTKVGBRTTIT-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- XXSCONYSQQLHTH-UHFFFAOYSA-N 9h-fluoren-9-ylmethanol Chemical compound C1=CC=C2C(CO)C3=CC=CC=C3C2=C1 XXSCONYSQQLHTH-UHFFFAOYSA-N 0.000 description 1
- 206010058808 Abdominal compartment syndrome Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010068388 Actinic elastosis Diseases 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000004990 Cardiorenal syndrome Diseases 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 208000010975 Dystrophic epidermolysis bullosa Diseases 0.000 description 1
- 206010014190 Eczema asteatotic Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000025500 Hutchinson-Gilford progeria syndrome Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000002623 Intra-Abdominal Hypertension Diseases 0.000 description 1
- 208000015814 Intrinsic Sleep disease Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 206010066945 Lichen striatus Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 206010058119 Neurogenic shock Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 208000000766 Pityriasis Lichenoides Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036087 Polymorphic light eruption Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000007932 Progeria Diseases 0.000 description 1
- 206010038470 Renal infarct Diseases 0.000 description 1
- 206010038548 Renal vein thrombosis Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010062553 Scleroderma renal crisis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 108700028909 Serum Amyloid A Proteins 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010044223 Toxic epidermal necrolysis Diseases 0.000 description 1
- 231100000087 Toxic epidermal necrolysis Toxicity 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- BMQYVXCPAOLZOK-UHFFFAOYSA-N Trihydroxypropylpterisin Natural products OCC(O)C(O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- OAOPYKHCTJEXOP-UHFFFAOYSA-N acetyl chloride;dichloromethane Chemical compound ClCCl.CC(Cl)=O OAOPYKHCTJEXOP-UHFFFAOYSA-N 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005263 alkylenediamine group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- OOCCDEMITAIZTP-UHFFFAOYSA-N allylic benzylic alcohol Natural products OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- ABZZOPIABWYXSN-UHFFFAOYSA-N cyclohex-3-en-1-ol Chemical compound OC1CCC=CC1 ABZZOPIABWYXSN-UHFFFAOYSA-N 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- WEIMJSIRDZDHAH-UHFFFAOYSA-N cyclopent-3-en-1-ol Chemical compound OC1CC=CC1 WEIMJSIRDZDHAH-UHFFFAOYSA-N 0.000 description 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 208000004298 epidermolysis bullosa dystrophica Diseases 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000003631 female germ line stem cell Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 231100000502 fertility decrease Toxicity 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000001368 germline stem cell Anatomy 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 201000011200 hepatorenal syndrome Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004966 intestinal stem cell Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000000738 kidney tubule Anatomy 0.000 description 1
- 206010024217 lentigo Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 206010024428 lichen nitidus Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 201000005857 malignant hypertension Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 229940100630 metacresol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000008437 mitochondrial biogenesis Effects 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 230000021125 mitochondrion degradation Effects 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- VMOWKUTXPNPTEN-UHFFFAOYSA-N n,n-dimethylpropan-2-amine Chemical compound CC(C)N(C)C VMOWKUTXPNPTEN-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000036562 nail growth Effects 0.000 description 1
- KPSSIOMAKSHJJG-UHFFFAOYSA-N neopentyl alcohol Chemical compound CC(C)(C)CO KPSSIOMAKSHJJG-UHFFFAOYSA-N 0.000 description 1
- BMQYVXCPAOLZOK-XINAWCOVSA-N neopterin Chemical compound OC[C@@H](O)[C@@H](O)C1=CN=C2NC(N)=NC(=O)C2=N1 BMQYVXCPAOLZOK-XINAWCOVSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000007996 nephrogenic syndrome of inappropriate antidiuresis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 206010033898 parapsoriasis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000010935 polish filtration Methods 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- ASUAYTHWZCLXAN-UHFFFAOYSA-N prenol Chemical compound CC(C)=CCO ASUAYTHWZCLXAN-UHFFFAOYSA-N 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000010963 scalable process Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 230000037322 slow-wave sleep Effects 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 231100000469 sperm hypomotility Toxicity 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000012030 stroop test Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- RKBCYCFRFCNLTO-UHFFFAOYSA-N triisopropylamine Chemical compound CC(C)N(C(C)C)C(C)C RKBCYCFRFCNLTO-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 238000004017 vitrification Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/38—Nucleosides
- C12P19/385—Pyrimidine nucleosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
Definitions
- Nicotinamide riboside is a pyridine-nucleoside form of niacin (i.e., vitamin B 3 ) that serves as a precursor to nicotinamide adenine dinucleotide (NAD + ). NAD + promotes cellular metabolism, mitochondrial function, and energy production.
- nicotinamide riboside is made through synthetic methods or fermentation processes. Because of its significant potential to confer health benefits when used as a dietary supplement, there exists a need to develop highly efficient and scalable processes for the manufacture of nicotinamide riboside.
- the present invention provides a method of preparing compound 3,
- the chlorinating agent is gaseous HCl or HCl in dioxane
- the present invention provides a method of preparing compound 4, comprising the steps of:
- ammonia reagent is methanolic ammonia or diethylamine.
- the invention provides a compound having the structure of Compound 4, made according to method described herein.
- the present invention provides a method of improving cellular health in a subject, comprising administering to the subject a compound having the structure of Compound 4, made according to method described herein.
- the present invention provides a method of improving sleep quality, stimulating or increasing REM sleep, or treating or preventing insomnia, desynchronosis, or a circadian rhythm sleep disorder in a subject, comprising administering to the subject a compound having the structure of Compound 4, made according to method described herein.
- the present invention provides a method of treating or preventing a motor neuron disease or ALS, or slowing or reversing the progression of motor neuron degeneration in a subject, comprising administering to the subject a compound having the structure of Compound 4, made according to method described herein.
- the present invention provides a method of improving fertility, treating or preventing infertility, inducing ovulation, increasing sperm count, or increasing lactation, comprising administering to the subject a compound having the structure of Compound 4, made according to method described herein.
- the present invention provides a method of treating or preventing kidney damage, acute kidney injury, or kidney disease, or increasing blood flow to the kidneys, comprising administering to the subject a compound having the structure of Compound 4, made according to method described herein.
- the present invention provides a method of treating or preventing liver damage or fatty liver, or decreasing the serum level of alanine transaminase (ALT) or aspartate transaminase (AST) in a subject, comprising administering to the subject a compound having the structure of Compound 4, made according to method described herein.
- ALT alanine transaminase
- AST aspartate transaminase
- acyl is art-recognized and refers to a group represented by the general formula hydrocarbyl-C(O)—, preferably alkyl-C(O)—.
- acetyl refers to a specific acyl group having the formula H 3 C—C(O)—. Acetyl may be abbreviated as “Ac—.”
- alkyl group or “alkane” is a straight chained or branched non-aromatic hydrocarbon which is completely saturated. Typically, a straight chained or branched alkyl group has from 1 to about 20 carbon atoms, preferably from 1 to about 10, or 1 to 6, unless otherwise defined. Examples of straight chained and branched alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, hexyl, pentyl and octyl. A C 1 -C 6 straight chained or branched alkyl group is also referred to as a “lower alkyl” group.
- C x-y when used in conjunction with a chemical moiety, such as alkyl is meant to include groups that contain from x to y carbons in the chain.
- C x-y alkyl refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups that contain from x to y carbons in the chain, including haloalkyl groups such as trifluoromethyl and 2,2,2-tirfluoroethyl, etc.
- C 0 alkyl indicates a hydrogen where the group is in a terminal position, a bond if internal.
- C 2-y alkenyl and C 2-y alkynyl refer to substituted or unsubstituted unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.
- a “trialkylamine” means a compound having the structure N(R 1 )(R 2 )(R 3 ), wherein R 1 , R 2 , and R 3 are each an alkyl group, and can be identical or different.
- Exemplary trialkylamine compounds include trimethylamine, trimethylamine, triisopropylamine, tributylamine, and isopropyldimethylamine.
- chlorinating agent means a reagent that provides a source of chlorine anions (i.e., Cl ⁇ ).
- exemplary chlorinating agents include sources of HCl, such as HCl gas or HCl in a solvent such as ethanol or dioxane.
- a chlorinating agent used in the methods of the invention is preferably HCl in dioxane.
- An alternative chlorinating agent that is preferably used in some embodiments of the methods of the invention is gaseous HCl (i.e., HCl (gas)).
- Nicotinamide is a molecule having the following structure:
- ammonia reagent means a reagent that provides a source of ammonia (i.e., NH 3 ), or an alkyl amine (such as methylamine), or a dialkylamine (such as diethylamine), or an alkylenediamine (such as ethylenediamine).
- Ammonia may be supplied as a gas (i.e., NH 3 (g)) or in a solution of an organic solvent, such as methanol, ethanol, isopropanol, dioxane, or tetrahydrofuran (THF).
- the term “ammonia reagent” also includes ammonia supplied in aqueous solution.
- the liquid material that passes through the filter is referred to herein as the “filtrate”.
- the solid material that collects is referred to herein as the “retentate.”
- administering means providing a pharmaceutical agent or composition to a subject, and includes, but is not limited to, administering by a medical professional and self-administering. Administration of a substance, a compound or an agent to a subject can be carried out using one of a variety of methods known to those skilled in the art.
- a compound or an agent can be administered, intravenously, arterially, intradermally, intramuscularly, intraperitoneally, subcutaneously, ocularly, sublingually, orally (by ingestion), intranasally (by inhalation), intraspinally, intracerebrally, and transdermally (by absorption, e.g., through a skin duct).
- a compound or agent can also appropriately be introduced by rechargeable or biodegradable polymeric devices or other devices, e.g., patches and pumps, or formulations, which provide for the extended, slow or controlled release of the compound or agent.
- Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods.
- a compound or an agent is administered orally, e.g., to a subject by ingestion.
- the orally administered compound or agent is in an extended release or slow release formulation, or administered using a device for such slow or extended release.
- pharmaceutically-acceptable carrier means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material.
- the term “subject” means a human or non-human animal selected for treatment or therapy.
- therapeutically-effective amount and “effective amount” as used herein means the amount of an agent which is effective for producing the desired therapeutic effect in at least a sub-population of cells in a subject at a reasonable benefit/risk ratio applicable to any medical treatment.
- Treating” a disease in a subject or “treating” a subject having a disease refers to subjecting the subject to a pharmaceutical treatment, e.g., the administration of a drug, such that at least one symptom of the disease is decreased or prevented from worsening.
- a therapeutic that “prevents” a disorder or condition refers to a compound that, when administered to a statistical sample prior to the onset of the disorder or condition, reduces the occurrence of the disorder or condition in the treated sample relative to an untreated control sample, or delays the onset or reduces the severity of one or more symptoms of the disorder or condition relative to the untreated control sample.
- This invention is based on the discovery of an efficient, scalable synthesis of nicotinamide riboside.
- the present invention provides a method for preparing compound 3,
- the chlorinating agent is gaseous HCl or HCl in dioxane
- the chlorinating agent is gaseous HCl (i.e., HCl (g)).
- the chlorinating agent is HCl in dioxane.
- step (a) occurs in a first solvent.
- the first solvent may be combined with compound 1 (i.e., a solution of compound 1 in the first solvent may be produced) prior to combination of compound 1 with the chlorinating agent.
- the first solvent, compound 1, and the chlorinating agent may be combined together simultaneously.
- the first solvent and the chlorinating agent may be combined first, followed by combination of that mixture with compound 1.
- the first solvent is a component of the chlorinating agent.
- the chlorinating agent is HCl in dioxane.
- dioxane is the first solvent.
- the chlorinating agent is HCl in dioxane and the first solvent is dioxane. In alternative embodiments, the chlorinating agent is HCl in dioxane and the first solvent is dichloromethane (DCM).
- DCM dichloromethane
- the first solvent may be acetonitrile.
- step (a) further comprises acetyl chloride (AcCl).
- Step (a) may be monitored by any reaction monitoring mechanism employed by persons of ordinary skill in the art, including thin layer chromatography, nuclear magnetic resonance spectroscopy, mass spectroscopy, and high performance liquid chromatography.
- the reaction mixture may be concentrated to remove or reduce the amounts of HCl and excess solvent present in the reaction mixture.
- a concentration step affords a concentrated crude material comprising compound 2.
- the method further comprises step (a′):
- the methods of the invention further comprise combining compound 2 and a second solvent.
- the concentrated crude material comprising compound 2 yielded from steps (a) and (a′) may be combined with a second solvent.
- the second solvent is acetonitrile.
- step (b) occurs in a second solvent.
- the second solvent may be a polar aprotic solvent.
- the second solvent may be acetonitrile.
- the method further comprises step (b′):
- the trialkylamine is tributylamine.
- the resultant reaction mixture comprising compound 3 is filtered, and the solids (i.e., retentate) are washed.
- the retentate comprises compound 3.
- the retentate may be washed with a cold solvent, such as cold acetonitrile or cold methanol.
- the method further comprises step (c):
- ammonia reagent is methanolic ammonia or diethylamine.
- the ammonia reagent is diethylamine.
- the ammonia reagent is methanolic ammonia.
- the methanolic ammonia is 1M, 2M, 3M, 4M, 5M, 6M, 7M, 8M, 9M, or 10M methanolic ammonia.
- the methanoic ammonia is 7M methanolic ammonia.
- step (c) occurs in a third solvent.
- the third solvent may be a polar protic solvent, such as an alcohol.
- the third solvent may, for example, be methanol, ethanol, isopropanol, or butanol. In certain preferred embodiments, the third solvent is methanol.
- step (c) takes place at a temperature below room temperature.
- step (c′) which occurs after step (c):
- the method of the invention further comprises step (c′′), which occurs after step (c′):
- the method further comprises rinsing the resultant retentate (i.e., the solids left behind after filtration) with cold methanol or ethanol.
- the method further comprises rinsing the resultant retentate (i.e., the solids left behind after filtration) with cold acetone.
- the method further comprises rinsing the resultant retentate (i.e., the solids left behind after filtration) with cold methyl tert butyl ether (MTBE).
- MTBE cold methyl tert butyl ether
- the reaction between the ammonia reagent and compound 3 may be monitored by any reaction monitoring mechanism employed by persons of ordinary skill in the art. Upon completion or significant progression of this reaction (i.e., upon formation of compound 4), the reaction mixture may be distilled, for example to remove the ammonia reagent and the third solvent. In certain such embodiments, compound 4 remains in the distillation pot. In further such embodiments, the remaining contents of the distillation may then by filtered and washed. In certain embodiments, the washing liquid is cold acetone and/or cold methanol.
- the invention provides a method of preparing compound 4,
- ammonia reagent is methanolic ammonia or diethylamine.
- the ammonia reagent is diethylamine.
- the ammonia reagent is methanolic ammonia.
- the methanolic ammonia is 1M, 2M, 3M, 4M, 5M, 6M, 7M, 8M, 9M, or 10M methanolic ammonia.
- the methanoic ammonia is 7M methanolic ammonia.
- step (c) occurs in a third solvent.
- the third solvent may be a polar protic solvent, such as an alcohol.
- the third solvent may, for example, be methanol, ethanol, isopropanol, or butanol. In certain preferred embodiments, the third solvent is methanol.
- step (c) takes place at a temperature below room temperature.
- step (c′) which occurs after step (c):
- the method of the invention further comprises step (c′′), which occurs after step (c′):
- the method further comprises rinsing the resultant retentate (i.e., the solids left behind after filtration) with cold methanol or ethanol.
- the method further comprises rinsing the resultant retentate (i.e., the solids left behind after filtration) with cold acetone.
- the method further comprises rinsing the resultant retentate (i.e., the solids left behind after filtration) with cold methyl tert butyl ether (MTBE).
- MTBE cold methyl tert butyl ether
- the method further comprises:
- the chlorinating agent is gaseous HCl or HCl in dioxane
- the chlorinating agent is gaseous HCl (i.e., HCl (g)).
- the chlorinating agent is HCl in dioxane.
- step (a) occurs in a first solvent.
- the first solvent may be combined with compound 1 (i.e., a solution of compound 1 in the first solvent may be produced) prior to combination of compound 1 with the chlorinating agent.
- the first solvent, compound 1, and the chlorinating agent may be combined together simultaneously.
- the first solvent and the chlorinating agent may be combined first, followed by combination of that mixture with compound 1.
- the first solvent is a component of the chlorinating agent.
- the chlorinating agent is HCl in dioxane.
- dioxane is the first solvent.
- the chlorinating agent is HCl in dioxane and the first solvent is dioxane. In alternative embodiments, the chlorinating agent is HCl in dioxane and the first solvent is dichloromethane (DCM).
- DCM dichloromethane
- the first solvent may be acetonitrile.
- step (a) further comprises acetyl chloride (AcCl).
- Step (a) may be monitored by any reaction monitoring mechanism employed by persons of ordinary skill in the art, including thin layer chromatography, nuclear magnetic resonance spectroscopy, mass spectroscopy, and high pressure liquid chromatography.
- the reaction mixture may be concentrated to remove or reduce the amounts of HCl and excess solvent present in the reaction mixture.
- a concentration step affords a concentrated crude material comprising compound 2.
- the method further comprises step (a′):
- the methods of the invention further comprise combining compound 2 and a second solvent.
- the concentrated crude material comprising compound 2 yielded from steps (a) and (a′) may be combined with a second solvent.
- the second solvent is acetonitrile.
- step (b) occurs in a second solvent.
- the second solvent may be a polar aprotic solvent.
- the second solvent may be acetonitrile.
- the method further comprises step (b′):
- the trialkylamine is tributylamine.
- the resultant reaction mixture comprising compound 3 is filtered, and the solids (i.e., retentate) are washed.
- the retentate comprises compound 3.
- the retentate may be washed with a cold solvent, such as cold acetonitrile or cold methanol.
- a “polar protic solvent” as used herein is a solvent having a dipole moment of about 1.4 to 4.0 D, and comprising a chemical moiety that participates in hydrogen bonding, such as an O—H bond or an N—H bond.
- exemplary polar protic solvents include methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, ammonia, water, and acetic acid.
- a “polar aprotic solvent” as used herein means a solvent having a dipole moment of about 1.4 to 4.0 D that lacks a hydrogen bonding group such as O—H or N—H.
- Exemplary polar aprotic solvents include acetone, N,N-dimethylformamide, acetonitrile, ethyl acetate, dichloromethane, tetrahydrofuran, and dimethylsulfoxide.
- non-polar solvent as used herein means a solvent having a low dialectric constant ( ⁇ 5) and low dipole moment of about 0.0 to about 1.2.
- exemplary nonpolar solvents include pentane, hexane, cyclohexane, benzene, toluene, chloroform, and diethyl ether.
- alcohols include, without limitation, methanol, ethanol, 2-butoxyethanol, propanol, allyl alcohol, methallyl alcohol, prenol, isopropanol, 2,2-dimethylpropan-1-ol, 2-methyl-2-phenylpropan-1-ol, butanol, isobutanol, sec-butanol, tert-butanol, 2-buten-1-ol, pentanol, 2-cyclopenten-1-ol, 4-cyclopenten-1-ol, cyclopentanol, 3-cyclopenten-1-ol, hexanol, cyclohexanol, 3-cyclohexen-1-ol, phenol, 1-naphthol, 2-naphthol, benzyl alcohol, menthol, 1,2-ethanediol, 9-fluorenylmethanol, resorcinol, meta-cresol, cinnamyl alcohol, and geraniol.
- the invention provides Compound 4, made according to any of the methods of preparation described herein.
- compound 4 is produced in a yield of about 30%, about 32%, about 34%, about 36%, about 38%, about 40%, about 42%, about 44%, about 46%, about 48%, about 50% or higher from compound 1.
- the purity of the compound is 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8% or higher.
- compositions described herein may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; or (3) sublingually.
- oral administration for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue
- parenteral administration for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution
- the composition comprises additional agents.
- the composition may comprise a nutritional agent, such as an antioxidant.
- a nutritional agent such as an antioxidant.
- pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- water soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like
- the formulations of the compounds described herein may be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated and the particular mode of administration.
- the amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the agent which produces a therapeutic effect.
- a formulation described herein comprises an excipient, including, but not limited to, cyclodextrins, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and polyanhydrides; and an agent of the invention.
- an aforementioned formulation renders orally bioavailable an agent of the invention.
- Methods of preparing these formulations or compositions may include the step of bringing into association a compound of the invention with the carrier and, optionally, one or more accessory ingredients.
- Liquid dosage forms for oral administration of the formulations provided herein include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents
- the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Formulations provided herein suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the invention as an active ingredient.
- a compound of the invention may also be administered as a bolus, electuary, or paste.
- the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as
- compositions may also comprise buffering agents.
- Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets, and other solid dosage forms of the pharmaceutical compositions described herein may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. Compositions described herein may also be formulated for rapid release, e.g., freeze-dried.
- compositions may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
- These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner.
- embedding compositions which can be used include polymeric substances and waxes.
- the active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
- compositions provided herein suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- aqueous and nonaqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate.
- polyols such as glycerol, propylene glycol, polyethylene glycol, and the like
- vegetable oils such as olive oil
- injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- the present invention provides a method of improving cellular health in a subject, comprising administering to the subject a compound made by the synthetic methods disclosed herein.
- the present invention provides methods for:
- such a method of treatment further comprises administering pterostilbene.
- the methods treat or prevent a circadian rhythm sleep disorder.
- the circadian rhythm sleep disorder can be extrinsic (e.g., shift work sleep disorder, desynchornosis) or intrinsic (e.g., advanced sleep phase disorder (ASPD), delayed sleep phase disorder (DSPD), irregular sleep-wake rhythm, and/or non-24-hour sleep-wake disorder (i.e., hypernychthemeral syndrome)).
- extrinsic e.g., shift work sleep disorder, desynchornosis
- intrinsic e.g., advanced sleep phase disorder (ASPD), delayed sleep phase disorder (DSPD), irregular sleep-wake rhythm, and/or non-24-hour sleep-wake disorder (i.e., hypernychthemeral syndrome)
- the subject may be male or female. In some embodiments, the subject is an adult (i.e., 18 years of age or older). The subject may be pediatric (i.e., less than 18 years of age). In some embodiments, the subject is a mammal, preferably, a human.
- the methods and compositions provided herein relate to improving sleep health and the quality of sleep in a subject in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside (compound 4) and/or pterostilbene.
- Sleep quality may refer to the “restfulness” of sleep (i.e., how rested an individual feels during waking hours). Sleep quality may refer to the quantity of sleep. Good sleep quality is associated with a wide range of positive outcomes such as better health, less daytime sleepiness, greater well-being and better psychological functioning.
- a subject has a score of 1, 2, or 3 on the Pittsburgh Sleep Quality Index (PSQI).
- PSQI Pittsburgh Sleep Quality Index
- PSQI Pittsburgh Sleep Quality Index
- REM sleep is a unique phase of sleep characterized by rapid movement of the eyes, low muscle tone throughout the body, and the propensity of the sleeper to dream vividly.
- the compositions and methods disclosed herein increase the total amount of time a subject is in REM sleep per sleep session (e.g., the total amount of time in REM per night). In some embodiments, the compositions and methods disclosed herein increase the amount of time a subject is in REM sleep per sleep cycle.
- Sleep progresses in a series of four or five more or less regular sleep cycles of non-REM and REM sleep throughout the night.
- the first sleep cycle is typically around 90 minutes in length, with the succeeding cycles averaging around 100-120 minutes, although some individuals may have longer or shorter average cycles.
- Each cycle follows the stages of non-REM sleep (stage 1-stage 2-stage 3) and then, after a period in deep stage 3 slow-wave sleep, back through the stages (stage 3-stage 2-stage 1). Then, instead of waking, the sleeper may enter a short period of REM sleep, before going back through non-REM stages in a new cycle.
- stimulating REM or increasing REM may refer to increasing the time a subject stays in REM sleep per sleep cycle or the total amount of time a subject is sleeping per day.
- the methods and compositions provided herein relate to the treatment and/or prevention of sleep disorders in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside (compound 4) and/or pterostilbene.
- a composition comprising nicotinamide riboside (compound 4) and/or pterostilbene.
- the subject has insomnia.
- Insomnia is a sleep disorder that is characterized by the inability to sleep.
- a subject with insomnia may have trouble falling asleep, staying asleep, or wake up too early and not be able to get back to sleep.
- insomnia may refer to short-term (acute) insomnia (i.e., the inability to sleep that lasts for days to weeks) or long-term (chronic) insomnia (i.e., the inability to sleep for one month or more).
- the insomnia is transient insomnia.
- Insomnia may be the result of stress, a traumatic event, nasal/sinus allergies, gastrointestinal problems, brain lesions and tumors, stroke, chronic pain, chronic fatigue syndrome, congestive heart failure, angina, acid-reflux disease (GERD), chronic obstructive pulmonary disease, asthma, endocrine disorders such as hyperthyroidism, arthritis, neurological conditions such as Parkinson's or Alzheimer's disease, low back pain, or genetics.
- the subject has restless leg syndrome.
- the subject has sleep apnea.
- the subject has a psychological condition that interferes with sleep, such as anxiety, depression, bipolar disorder, schizophrenia, posttraumatic stress disorder (PTSD), and/or attention deficit hyperactivity disorder (ADHD).
- insomnia is a side effect of medication.
- medications that may cause insomnia include, but are not limited to, corticosteroids, alpha blockers, beta blockers, SSRI antidepressants, ACE inhibitors, cholinesterase inhibitors, second generation (non-sedating) H1 agonists, or glucosamine/chondroitin.
- Circadian rhythms regulate the timing of periods of sleepiness and wakefulness throughout the day. Circadian rhythms are endogenously generated, although they can be modulated by external cues such as sunlight and temperature. Circadian rhythms are important in determining the sleeping and feeding patterns of all animals, including human beings. There are clear patterns of brain wave activity, hormone production, cell regeneration and other biological activities linked to this daily cycle, and an irregular circadian rhythm may lead to a disturbance any of the previously mentioned processes.
- the subject has a circadian rhythm sleep disorder.
- the circadian rhythm sleep disorder may be extrinsic (e.g., the result of environmental influences or circumstances) or intrinsic (e.g., the result of genetics or not the result of circumstances).
- An example of an extrinsic circadian sleep disorder includes shift work sleep disorder, which often affects individuals who work nights or in rotating shifts.
- Intrinsic sleep disorders include advanced sleep phase disorder (ASPD), delayed sleep phase disorder (DSPD), irregular sleep-wake rhythm, and/or non-24-hour sleep-wake disorder (i.e., hypernychthemeral syndrome)).
- ASPD is characterized by difficulty staying awake in the evening and difficulty staying asleep in the morning.
- DSPD is characterized by a much later than normal timing of sleep onset and offset and a period of peak alertness in the middle of the night.
- Non-24-hour sleep-wake disorder or hypernychthemeral syndrome, is a sleep disorder wherein the affected individual's sleep occurs later and later each day, with the period of peak alertness also continuously moving around the clock from day to day.
- Jet lag is a temporary sleep disorder caused by crossing time zones (e.g., during an airplane flight), and is often the result of disruption to the circadian rhythms of the body. Jet lag may occur any time the body's internal clock is out of sync with cues from a new time zone. Cues can include light exposure and eating times. General symptoms include fatigue and disorientation, interrupted sleep, confusion, mood changes, and pain in limbs.
- compositions disclosed herein may be varied so as to obtain an amount of nicotinamide riboside and/or pterostilbene that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the subject continuously self-administers the compounds disclosed herein.
- the subject may take a compound disclosed herein as needed.
- administration of the composition comprises administration of the composition in one or more dose(s). In some embodiments, administration of the composition comprises administration of the composition in one or more, five or more, ten or more, twenty or more, thirty or more, forty or more, fifty or more, one hundred or more, or one thousand or more dose(s).
- the dose comprises at least 25 mg, at least 50 mg, at least 75 mg, at least 100 mg, at least 125 mg, at least 150 mg, at least 200 mg, at least 225 mg, at least 250 mg, at least 275 mg, at least 300 mg, at least 325 mg, at least 350 mg, at least 375 mg, at least 400 mg, at least 425 mg, at least 450 mg, at least 475 mg, at least 500 mg, at least 550 mg, at least 600 mg, at least 650 mg, at least 700 mg, at least 750 mg, at least 800 mg, or at least 850 mg nicotinamide riboside (compound 4).
- the dose comprises at least 5 mg, at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg, at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least 60 mg, at least 65 mg, at least 70 mg, at least 75 mg, at least 80 mg, at least 90 mg, at least 95 mg, at least 100 mg, at least 110 mg, at least 120 mg, at least 130 mg, at least 140 mg, at least 150 mg, at least 160 mg, least 170 mg, at least 180 mg, at least 190 mg, at least 200 mg, or at least 250 mg of pterostilbene.
- compositions disclosed herein may be administered over any period of time effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the period of time may be at least 1 day, at least 10 days, at least 20 days, at least 30, days, at least 60 days, at least three months, at least six months, at least a year, at least three years, at least five years, or at least ten years.
- the dose may be administered when needed, sporadically, or at regular intervals. For example, the dose may be administered monthly, weekly, biweekly, triweekly, once a day, or twice a day.
- the present invention provides methods of:
- such a method of treatment further comprises administering pterostilbene.
- the motor neuron disease is ALS, hereditary spastic paraplegia (HSP), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), progressive bulbar palsy (PBP), pseudobulbar palsy, or a spinal muscular atrophy.
- HSP hereditary spastic paraplegia
- PLS primary lateral sclerosis
- PMA progressive muscular atrophy
- PBP progressive bulbar palsy
- pseudobulbar palsy or a spinal muscular atrophy.
- the subject may have or be predisposed to a motor neuron disease (e.g., amyotrophic lateral sclerosis (ALS), such as medulla ALS or brainstem ALS).
- a motor neuron disease or disorder may be any disease or disorder that affects the function or structure of motor neuron.
- a motor neuron diseases include progressive diseases that result in loss of function of motor neurons, or nerves, in the brain and spinal cord. Examples of motor neuron diseases include amyotrophic lateral sclerosis (ALS), hereditary spastic paraplegia (HSP), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), progressive bulbar palsy (PBP), pseudobulbar palsy, or a spinal muscular atrophy.
- HSP hereditary spastic paraplegia
- PLS primary lateral sclerosis
- PMA progressive muscular atrophy
- PBP progressive bulbar palsy
- pseudobulbar palsy or a spinal muscular atrophy.
- a motor neuron disease may affect the upper
- compositions disclosed herein may be varied so as to obtain an amount of nicotinamide riboside (compound 4) and/or pterostilbene that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- compound 4 nicotinamide riboside
- pterostilbene pterostilbene
- administration of the composition comprises administration of the composition in one or more dose(s). In some embodiments, administration of the composition comprises administration of the composition in one or more, five or more, ten or more, twenty or more, thirty or more, forty or more, fifty or more, one hundred or more, or one thousand or more dose(s).
- the dose comprises at least 100 mg, at least 200 mg, at least 300 mg, at least 400 mg, at least 500 mg, at least 600 mg, at least 700 mg, at least 800 mg, at least 900 mg, at least 1000 mg, at least 1100 mg, at least 1200 mg, at least 1300 mg, at least 1400 mg, at least 1500 mg, at least 1600 mg, at least 1700 mg, at least 1800 mg, at least 1900 mg, at least 2000 mg, at least 2100 mg, at least 2200 mg, at least 2300 mg, at least 2400 mg, at least 2500 mg, at least 2600 mg, at least 2700 mg, at least 2800 mg, at least 2900 mg, or at least 3000 mg, of nicotinamide riboside compound 4).
- the dose comprises at least 5 mg, at least 10, at least 20 mg, at least 30 mg, at least 40 mg, at least 50 mg, at least 60 mg, at least 80 mg, at least 100 mg, at least 120 mg, at least 140 mg, at least 160 mg, at least 180 mg, at least 200 mg, at least 220 mg, at least 240 mg, at least 260 mg, at least 280 mg, at least 300 mg, at least 320 mg, at least 340 mg, at least 360 mg, at least 380 mg, at least 400 mg, at least 500 mg, at least 600 mg, at least 700 mg, at least 800 mg, at least 900 mg, or at least 1000 mg of pterostilbene.
- compositions disclosed herein may be administered over any period of time effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the period of time may be at least 1 day, at least 10 days, at least 20 days, at least 30, days, at least 60 days, at least three months, at least six months, at least a year, at least three years, at least five years, or at least ten years.
- the dose may be administered when needed, sporadically, or at regular intervals. For example, the dose may be administered monthly, weekly, biweekly, triweekly, once a day, or twice a day.
- the subject is given a test to measure the general progression or symptomatic progression of a motor neuron disease.
- the subject is given a motor function test and/or a cognition and conduct function test.
- the motor function test may be Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R).
- the cognition and conduct test may be Complutense Verbal Learning Test (TAVEC), Symbol Digit Modalities Test (SDMT), Verbal Fluency Test, Digit Span (Wechsler Memory Scale III), D2 Attention Test, Wechsler Memory Scale III for Letters and Numbers, London Tower Test, Stroop test, Frontal System Behavior Scale (FrSBe), and/or Brief Test (subjective conduct).
- subjects are given both motor function and cognitive function tests. Motor function or cognitive functions tests may be given to the subject once or multiple times.
- the method further comprises measuring a feature (e.g., a feature associated with inflammation) in the subject.
- the feature is measured in a blood test.
- features that may be tested are the level of a cytokine, level of amyloid A protein, level of macrophage activation marker neopterin, level of creatine phosphokinase (CPK), level of erythrocyte sedimentation rate, level of C-reactive protein, plasma viscosity, and/or white blood cell count.
- the cytokine is proinflammatory cytokine.
- the cytokine is an anti-inflammatory cytokine. Examples of cytokines include, but are not limited to, TNF ⁇ , IFN ⁇ , IL-1, IL-6, IL-8, or TGF ⁇ .
- the method further comprises administering a fatty acid supplement to the subject.
- the fatty acid supplement comprises an oil.
- the oil may be processed (e.g., refined, bleached, or deodorized). In other embodiments, the oil is unprocessed or a virgin oil.
- the fatty acid supplement is derived or fractionated from a source to yield separated fatty acids.
- the oil is a coconut oil.
- coconut oil as used herein, may include any oil produced by the nut of the coconut palm.
- Fatty acids found in the supplements disclosed herein may be short-chain fatty acids, medium chain fatty acids, or long chain fatty acids.
- Exemplary fatty acids that may be found in the supplement include, but are not limited to, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, and/or linolenic acid.
- the fatty acid supplement disclosed herein may comprise saturated fatty acids, unsaturated fatty acids, monounsaturated fatty acids, and/or polyunsaturated fatty acids.
- the fatty acid supplement may comprise a hydrogenated oil.
- Fatty acid supplements may comprise one or more fatty acid(s). Actual dosage levels and administration regimen of the fatty acid supplement disclosed herein may be varied so as to obtain an amount of fatty acid supplement that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the present invention provides methods relating to:
- such a method of treatment further comprises administering pterostilbene.
- improving fertility or treating and/or preventing infertility comprises inducing ovulation and/or oocyte and follicle maturation in a female subject. In some embodiments, improving fertility or treating and/or preventing infertility comprising increasing sperm count and/or sperm motility in a male subject.
- the subject is a mammal (e.g., a human, a non-human mammal).
- the subject may be male or female.
- the subject has impaired fertility (e.g., reduced sperm count, reduced sperm motility, reduced ovulation, reduced follicle and/or oocyte maturation).
- the subject is infertile or sterile.
- a composition disclosed herein i.e., a composition comprising nicotinamide riboside (compound 4) and/or pterostilbene.
- Increasing sperm count may be achieved by increasing the concentration of spermatozoa in seminal fluid, increasing the absolute number of spermatozoa in semen and/or increasing the volume of semen per ejaculate.
- the methods and compositions disclosed herein may increase overall sperm count by increasing or inducing spermatogenesis.
- administering the compositions disclosed herein increase or improve sperm motility (e.g., increasing the percentage of spermatozoa moving in semen or increasing the amount of time spermatozoa are moving) in a subject. In some embodiments, administering the compositions disclosed herein maintains or improves overall sperm health, sperm count, and/or sperm motility in the testes and/or epididymis post spermatogenesis.
- provided herein are methods of inducing and/or increasing the likelihood of ovulation in a subject by administering to the subject (e.g., a subject in need thereof) a composition disclosed herein (i.e., a composition comprising nicotinamide riboside (compound 4) and/or pterostilbene).
- a composition disclosed herein i.e., a composition comprising nicotinamide riboside (compound 4) and/or pterostilbene.
- methods of inducing follicle and oocyte maturation e.g., folliculogenesis
- a composition disclosed herein i.e., a composition comprising nicotinamide riboside (compound 4) and/or pterostilbene.
- compositions and methods to aid in in vitro fertilization procedures and practices provide herein are methods of treating, preserving, or improving gamete (i.e., sperm and/or oocyte) likelihood of fertilization in an in vitro procedure.
- gamete i.e., sperm and/or oocyte
- compositions disclosed herein are added to semen (e.g., semen obtained from a donor subject) in preparation of for artificial insemination or intrauterine insemination (IUI).
- IUI intrauterine insemination
- compositions disclosed herein are added to semen in preparation intracytoplasic sperm injection into an oocyte.
- compositions disclosed herein may be used to enhance mitochondrial numbers, mitochondrial activity, cellular energy levels or cellular energy-producing potential in oocytes, postnatal female germline stem cells (also referred to herein as OSCs) and/or preimplantation embryos prior to conducting and/or following methods of in vitro fertilization.
- OSCs postnatal female germline stem cells
- preimplantation embryos prior to conducting and/or following methods of in vitro fertilization.
- OSCs postnatal female germline stem cells
- preimplantation embryos prior to conducting and/or following methods of in vitro fertilization.
- provided herein are methods of increasing the overall viability of an oocyte removed from a subject (e.g., an oocyte removed in preparation for in vitro fertilization).
- an oocyte is treated or stored with a composition disclosed herein prior to in vitro fertilization.
- methods of in vitro fertilization the method involving the steps of: incubating an oocyte from a subject with a composition disclosed herein; and fertilizing the oocyte in vitro to form a zygote.
- the methods provided herein include a method of in vitro fertilization, the method involving the steps of (a) incubating an OSC from a subject with composition disclosed herein; (b) obtaining a composition containing OSC mitochondria from the OSC; (c) transferring the composition into an isolated oocyte (e.g., an oocyte extracted from a subject); and (d) fertilizing the oocyte in vitro to form a zygote.
- an isolated oocyte e.g., an oocyte extracted from a subject
- fertilizing the oocyte in vitro to form a zygote.
- the composition disclosed herein may be added to a solution used for in vitro fertilization procedures for oocyte preparation and/or storage, such as cell culture medium, oocyte retrieval solution, oocyte washing solution, oocyte in vitro maturation medium, ovarian follicle in vitro maturation medium, oocyte in vitro fertilization medium, embryo culture medium, cleavage medium, vitrification solution, cryopreservation solution and/or embryo thawing medium.
- a solution used for in vitro fertilization procedures for oocyte preparation and/or storage such as cell culture medium, oocyte retrieval solution, oocyte washing solution, oocyte in vitro maturation medium, ovarian follicle in vitro maturation medium, oocyte in vitro fertilization medium, embryo culture medium, cleavage medium, vitrification solution, cryopreservation solution and/or embryo thawing medium.
- Gametes may be stored for any period of time with the compositions disclosed herein before in vitro fertilization is performed.
- a composition disclosed herein i.e., a composition comprising nicotinamide riboside (compound 4) and/or pterostilbene.
- increasing lactation comprising increasing the rate at which milk is secreted and/or produced from the mammary glands of a subject.
- increasing lactation comprises increasing the volume of secreted milk in the subject.
- the subject is a human.
- the subject is a non-human animal, such as a dairy animal (e.g., a cow, a buffalo, a goat, a sheep, a camel).
- kits for improving animal fecundity and/or breeding outcomes in animal husbandry by administering the compositions disclosed herein to a subject(s) (e.g., a non-human subject).
- a subject e.g., a non-human subject, such as a domesticated animal.
- the subject is a mammal.
- the subject may be a rodent, lagomorph, feline, canine, porcine, ovine, bovine, equine, or primate.
- a composition disclosed herein may be administered to a female subject to increase number of offspring per litter or reproductive cycle.
- the compositions disclosed herein may be administered to male subjects to increase spermatozoa production to obtain semen samples with increased virility for use in artificial insemination.
- compositions disclosed herein may be varied so as to obtain an amount of nicotinamide riboside and/or pterostilbene that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- administration of the composition comprises administration of the composition in one or more dose(s). In some embodiments, administration of the composition comprises administration of the composition in one or more, five or more, ten or more, twenty or more, thirty or more, forty or more, fifty or more, one hundred or more, or one thousand or more dose(s).
- the dose comprises at least 25 mg, at least 50 mg, at least 75 mg, at least 100 mg, at least 125 mg, at least 150 mg, at least 200 mg, at least 225 mg, at least 250 mg, at least 275 mg, at least 300 mg, at least 325 mg, at least 350 mg, at least 375 mg, at least 400 mg, at least 425 mg, at least 450 mg, at least 475 mg, at least 500 mg, at least 550 mg, at least 600 mg, at least 650 mg, at least 700 mg, at least 750 mg, at least 800 mg, or at least 850 mg of nicotinamide riboside (compound 4).
- the dose comprises at least 5 mg, at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg, at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least 60 mg, at least 65 mg, at least 70 mg, at least 75 mg, at least 80 mg, at least 90 mg, at least 95 mg, at least 100 mg, at least 110 mg, at least 120 mg, at least 130 mg, at least 140 mg, at least 150 mg, at least 160 mg, least 170 mg, at least 180 mg, at least 190 mg, at least 200 mg, or at least 250 mg of pterostilbene.
- compositions disclosed herein may be administered over any period of time effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the period of time may be at least 1 day, at least 10 days, at least 20 days, at least 30, days, at least 60 days, at least three months, at least six months, at least a year, at least three years, at least five years, or at least ten years.
- the dose may be administered when needed, sporadically, or at regular intervals. For example, the dose may be administered monthly, weekly, biweekly, triweekly, once a day, or twice a day.
- the present invention provides methods relating to:
- such a method of treatment further comprises administering pterostilbene.
- the kidney damage is the result of cancer, decreased blood flood to the kidneys (i.e., ischemia), back up of urine in the kidneys, sepsis, trauma, autoimmune disease, drug-induced toxicity (e.g., non-steroidal anti-inflammatory (NSAID) induced nephrotoxicity), lead poisoning, and/or severe dehydration.
- ischemia i.e., ischemia
- drug-induced toxicity e.g., non-steroidal anti-inflammatory (NSAID) induced nephrotoxicity
- lead poisoning e.g., NSAID
- the acute kidney injury is the result of decreased blood flow to the kidneys (i.e., ischemic injury).
- Decreased blood flow to the kidneys may be a result of hypotension, blood loss, severe diarrhea, heat attack, heart failure, deceased heart function, organ failure, drug-induced nephrotoxicity (e.g., NSAID induced nephrotoxicity), allergic reactions, bums, trauma (e.g., blunt trauma), and/or surgery.
- the acute kidney injury is the result of cancer (e.g., multiple myeloma), sepsis, vasculitis, interstitial nephritis, scleroderma, tubular necrosis, glomerulonephritis, or thrombotic microangiopathy.
- the acute kidney injury is the result of blockage of the urinary tract. Blockage of the urinary tract may be caused by bladder cancer, prostate cancer, cervical cancer, an enlarged prostate, kidney stones, or blood clots in the urine.
- the chronic kidney disease is the result of an immune system disease (e.g., lupus), long term viral disease (e.g., HIV/AIDS, hepatitis B, or hepatitis C), urinary tract infections, polycystic kidney disease, and/or inflammation of glomeruli.
- an immune system disease e.g., lupus
- long term viral disease e.g., HIV/AIDS, hepatitis B, or hepatitis C
- urinary tract infections e.g., polycystic kidney disease, and/or inflammation of glomeruli.
- kidney damage may refer to a medical condition of impaired kidney function in which the kidneys fail to adequately filter metabolic wastes from the blood.
- kidney damage is also indicative of kidney failure.
- conditions that may cause kidney damage include, but are not limited to decreased blood flood to the kidneys, back up of urine in the kidneys, sepsis, trauma (e.g., such as blunt trauma), an autoimmune disease, drug-induced nephrotoxicity (e.g., NSIAD induced nephrotoxicity), heavy mental poisoning (e.g., lead poisoning), or severe dehydration.
- kidney injury is an episode of kidney failure or kidney damage that happens within a few hours or a few days.
- Acute kidney injury as used herein, may be characterized by abrupt deterioration in kidney function.
- the subject has acute kidney injury, and the acute kidney injury may manifest by an increase in serum creatinine level with or without reduced urine output.
- the subject has increased serum creatinine levels.
- the subject may have reduced urine output.
- the subject has acute kidney injury, and the acute kidney injury may be prerenal (e.g., caused by decreased renal blood flow), intrinsic renal (e.g., caused by a process within the kidneys), or postrenal (e.g., caused by inadequate drainage of urine distal to the kidneys).
- prerenal e.g., caused by decreased renal blood flow
- intrinsic renal e.g., caused by a process within the kidneys
- postrenal e.g., caused by inadequate drainage of urine distal to the kidneys.
- Acute kidney injury or kidney damage may be a result of use (e.g., overuse) of medications, such as NSAIDs, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, cyclosporine, diuretics, tacrolimus, penicillin analogues, cephalosporins, sulfonamides, ciprofloxacin, acyclovir, rifampin, phenytoin, interferon, or proton pump inhibitors.
- medications such as NSAIDs, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, cyclosporine, diuretics, tacrolimus, penicillin analogues, cephalosporins, sulfonamides, ciprofloxacin, acyclovir, rifampin, phenytoin, interferon, or proton pump inhibitors.
- kidney damage causes of acute kidney injury and kidney damage include cardiorenal syndrome, hepatorenal syndrome, abdominal compartment syndrome, hypercalcemia, sepsis, neurogenic shock, infections of the renal parenchyma, glomerulonephritis, viral infections (such as Epstein-Barr virus infections or cytomegalovirus infections), bacterial infections (e.g., bacterial infections caused by bacteria of the Streptococcus or Legionella species), or fungal infections (e.g., fungal infections caused by candidiasis or histoplasmosis).
- the acute renal injury and/or kidney damage is caused by a systemic disease, such as sarcoidosis or lupus.
- conditions that cause acute kidney injury and kidney damage include cancer (e.g., multiple myeloma), prolonged hypotension, renal vein thrombosis, malignant hypertension, scleroderma renal crisis, renal atheroembolic disease, renal infarction vasculitis, interstitial nephritis, scleroderma, and or conditions that cause inflammation of or damage to the kidney tubules, such as tubular necrosis, glomerulonephritis, or thrombotic microangiopathy.
- cancer e.g., multiple myeloma
- prolonged hypotension e.g., prolonged hypotension, renal vein thrombosis, malignant hypertension, scleroderma renal crisis, renal atheroembolic disease, renal infarction vasculitis, interstitial nephritis, scleroderma
- conditions that cause inflammation of or damage to the kidney tubules such as tubular necrosis, glomerulonephritis, or
- the acute kidney injury and/or kidney damage is caused by a decrease in blood flow to the kidney.
- Conditions that may cause a decrease in blood flow to the kidneys includes, for example, blood loss, severe diarrhea, heat attack, heart failure, deceased heart function, organ failure, allergic reactions, bums, and/or trauma.
- the subject has undergone surgery, and the subject's blood vessels have been clamped, leading to a decrease of blood flow to the kidneys.
- the acute kidney injury or kidney damage is the result of a blockage of the urinary tract.
- a blockage of the urinary tract may be the result of, for example, neurogenic bladder, retroperitoneal fibrosis, bladder cancer, prostate cancer, cervical cancer, an enlarged prostate, kidney stones, blood clots, or tumors.
- kidney disease is any condition that affects the kidney's ability to filter compounds out of blood, filter extra water out of blood, and/or help control blood pressure.
- Kidney disease may be caused by diabetes, hypertension, a systemic disease (e.g., lupus), viral disease (e.g., HIV/AIDS, hepatitis B, or hepatitis C), urinary tract infections, a genetic disease, such as polycystic kidney disease, or any condition that results in the inflammation of kidney glomeruli.
- kidney function may be measured prior, during or after administration of a composition disclosed herein.
- Kidney function may be evaluated as a function of glomerular filtration rate, urine output, or the level of other biomedical markers of kidney health, such as creatinine, urea, nitrogen, phosphorus, or potassium. Markers such as creatinine, urea, nitrogen, phosphorus, or potassium may be measured in the urine or through a blood test.
- compositions disclosed herein may be varied so as to obtain an amount of nicotinamide riboside (compound 4) and/or pterostilbene that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- compound 4 nicotinamide riboside
- pterostilbene pterostilbene
- administration of the composition comprises administration of the composition in one or more dose(s). In some embodiments, administration of the composition comprises administration of the composition in one or more, five or more, ten or more, twenty or more, thirty or more, forty or more, fifty or more, one hundred or more, or one thousand or more dose(s).
- the dose comprises at least 25 mg, at least 50 mg, at least 75 mg, at least 100 mg, at least 125 mg, at least 150 mg, at least 200 mg, at least 225 mg, at least 250 mg, at least 275 mg, at least 300 mg, at least 325 mg, at least 350 mg, at least 375 mg, at least 400 mg, at least 425 mg, at least 450 mg, at least 475 mg, at least 500 mg, at least 550 mg, at least 600 mg, at least 650 mg, at least 700 mg, at least 750 mg, at least 800 mg, or at least 850 mg of nicotinamide riboside (Compound 4).
- the dose comprises at least 5 mg, at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg, at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least 60 mg, at least 65 mg, at least 70 mg, at least 75 mg, at least 80 mg, at least 90 mg, at least 95 mg, at least 100 mg, at least 110 mg, at least 120 mg, at least 130 mg, at least 140 mg, at least 150 mg, at least 160 mg, least 170 mg, at least 180 mg, at least 190 mg, at least 200 mg, or at least 250 mg of pterostilbene.
- compositions disclosed herein may be administered over any period of time effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the period of time may be at least 1 day, at least 10 days, at least 20 days, at least 30, days, at least 60 days, at least three months, at least six months, at least a year, at least three years, at least five years, or at least ten years.
- the dose may be administered when needed, sporadically, or at regular intervals. For example, the dose may be administered monthly, weekly, biweekly, triweekly, once a day, or twice a day.
- the present invention provides methods relating to treating and/or preventing liver related diseases and disorders and for improving liver health in a subject by administering to the subject Compound 4, as prepared by the synthetic methods disclosed herein.
- the invention provides a method of:
- such a method of treatment further comprises administering pterostilbene.
- the liver damage is the result of cancer (e.g., liver cancer, bile duct cancer and/or a liver adenoma), cirrhosis, viral infection (e.g., hepatitis A infection, a hepatitis B infection and/or a hepatitis E infection), congenital disorders of metabolism, trauma, autoimmune disease (e.g., autoimmune hepatitis, primary biliary cirrhosis, or primary sclerosing cholangitis), hemochromatosis, hyperoxaluria, oxalosis, Wilson's disease and/or drug-induced hepatotoxicity (e.g., alcohol-induced hepatotoxicity and/or acetaminophen-induced hepatotoxicity).
- cancer e.g., liver cancer, bile duct cancer and/or a liver adenoma
- viral infection e.g., hepatitis A infection, a hepatitis B infection and/or
- compositions disclosed herein i.e., a composition comprising nicotinamide riboside and/or pterostilbene.
- the subject may have or be predisposed to liver damage and/or fatty liver.
- Liver damage may result from any condition that causes the cells of the liver (i.e., hepatocytes) to die or otherwise not function normally.
- conditions that may cause liver damage include, but are not limited to, cancer (e.g., liver cancer, bile duct cancer, or a liver adenoma), trauma, congenital metabolic disorders (e.g., genetic metabolic disorders resulting in an enzyme deficiency), vascular injury, cirrhosis, a viral infection (e.g., hepatitis A, hepatitis B, hepatitis E), an autoimmune disease (e.g., autoimmune hepatitis, primary biliary cirrhosis, or primary sclerosing cholangitis), hemochromatosis, hyperoxaluria, oxalosis, Wilson's disease, or drug-induced hepatotoxicity (e.g., alcohol-induced hepatotoxicity
- ALT and ALT are reasonably sensitive indicators of liver damage or injury frorn different types of diseases or conditions, and they are often measured in liver tests or liver blood tests. Elevated levels of AST and ALT are associated with liver damage and liver malfunction.
- ALT is decreased in the subject by at least 0.1 U/L, at least 0.2 U/L, at least 0.3 U/L, at least 0.4 U/L, at least 0.5 U/L, at least 0.6 U/L, at least 0.7 U/L, at least 0.8 U/L, at least 0.9 U/L, at least 01.0 U/L, 1.1 U/L, at least 1.2 U/L, at least 1.3 U/L, at least 1.4 U/L, at least 1.5 U/L, at least 1.6 U/L, at least 1.7 U/L, at least 1.8 U/L, at least 1.9 U/L, at least 2.0 U/L, 2.1 U/L, at least 2.2 U/L, at least 2.3 U/L, at least 2.4 U/L, at least 2.5 U/L, at least 2.6 U/L, at least 2.7 U/L, at least 2.8 U/L, at least 2.9 U/L, at least 3.0 U/L, at least 3.5 U/L,
- the ALT is decreased by at least 0.1 U/L, at least 0.2 U/L, at least 0.3 U/L, at least 0.4 U/L, at least 0.5 U/L, at least 0.6 U/L, at least 0.7 U/L, at least 0.8 U/L, at least 0.9 U/L, at least 01.0 U/L, 1.1 U/L, at least 1.2 U/L, at least 1.3 U/L, at least 1.4 U/L, at least 1.5 U/L, at least 1.6 U/L, at least 1.7 U/L, at least 1.8 U/L, at least 1.9 U/L, at least 2.0 U/L, 2.1 U/L, at least 2.2 U/L, at least 2.3 U/L, at least 2.4 U/L, at least 2.5 U/L, at least 2.6 U/L, at least 2.7 U/L, at least 2.8 U/L, at least 2.9 U/L, at least 3.0 U/L, at least 3.5 U/L, 4.0
- Nicotinamide adenine dinucleotide (NAD + ) is a coenzyme that participates in many metabolic reactions. NAD + plays an important role in transcription regulation, longevity, and age-associated diseases. NAD + levels decrease with age, while increased NAD + levels are associated with robust health. In some embodiments, provided herein are methods of increasing the amount of NAD + of a subject by administering a composition disclosed herein.
- NAD + may increase by at least 1.0 ⁇ g/mL, at least 2.0 ⁇ g/mL, at least 3.0 ⁇ g/mL, at least 4.0 ⁇ g/mL, at least 5.0 ⁇ g/mL, at least 6.0 ⁇ g/mL, at least 7.0 ⁇ g/mL, at least 8.0 ⁇ g/mL, at least 9.0 ⁇ g/mL, at least 10.0 ⁇ g/mL, at least 11.0 ⁇ g/mL, at least 12.0 ⁇ g/mL, at least 13.0 ⁇ g/mL, at least 14.0 ⁇ g/mL, at least 15.0 ⁇ g/mL, at least 16 ⁇ g/mL, at least 17 ⁇ g/mL, at least 18 ⁇ g/mL, at least 19 ⁇ g/mL, at least 20 ⁇ g/mL, at least 21 ⁇ g/mL, at least 22 ⁇ g/mL, at least 23 ⁇ g/mL, at least 24
- the subject's diastolic blood pressure decreases by at least 1 mmHg, at least 1.5 mmHg, at least 2 mmHg, at least 2.5 mmHg, at least 3 mmHg, at least 3.5 mmHg, at least 4.0 mmHg, at least 4.5 mmHg, or at least 5 mmHg after administration of the composition.
- the invention also provides a method of treating a disease comprising administering to a subject compound 4 and/or pterostilbene.
- the disease is a neurodegenerative disease.
- exemplary neurodegenerative diseases include Alzheimer's, Parkinson's, and Huntington's Disease.
- the disease is a skin disorder.
- Skin disorders may be caused by exposure to the sun; exemplary such disorders are selected from the group consisting of actinic keratoses, lentigines or age spots, seborrheic keratoses, sun burn, photosensitivity, moles, polymorphous light eruption, solar elastosis or wrinkles, skin cancer (such as melanoma, squamous cell carcinoma, and basal cell carcinoma), and freckles.
- Skin disorders may also be caused by inflammation; exemplary such disorders are selected from the group consisting of psoriasis, contact dermatitis, atopic dermatitis, seborrheic dermatitis, puttotic eczema, discoid eczema, hand eczema, gravitational/varicose eczema, eczematous drug eruptions, lichen simplex, acne, lichen planus, pityriasis lichenoides, keratosis lichenoides chronica, lichen nitidus , lichen striatus , mycosis fungoides, erythroderma, erythema multiforme, Stevens-Johnson Syndrome, vasculitis, and toxic epidermal necrolysis.
- a skin disorder may be caused by autoimmune disease is selected from the group consisting of pyoderma gangrenosum, systemic lupus erythematosus, eosinophilic fasciitis, scleroderma, pemphigus vulgaris, bullous pemphigoid, alopecia areata, vitiligo, psoriasis, dermatomyositis, and dystrophic epidermolysis bullosa.
- autoimmune disease is selected from the group consisting of pyoderma gangrenosum, systemic lupus erythematosus, eosinophilic fasciitis, scleroderma, pemphigus vulgaris, bullous pemphigoid, alopecia areata, vitiligo, psoriasis, dermatomyositis, and dystrophic epidermolysis bullosa.
- the disease is obesity or diabetes.
- the methods may also enable lipid lowering and blood pressure reduction.
- the disease is muscle wasting or sarcopenia.
- the disease is an autoimmune disease such as arthritis or lupus.
- the disease is mitochondrial dysfunction or disease.
- the disease is an accelerated aging disease such as progeria.
- the disease is chemotherapy induced neuropathy, or cognitive decline.
- the methods may also enable pain reduction.
- the disease is a cancer such as breast cancer, colon cancer, etc.
- the invention provides methods that promote sirtuin activation, NAD + boosting, PARP activation, autophagy and mitophagy, or mitochondrial biogenesis.
- the invention provides methods of promoting wellness comprising administering to a subject compound 4 and/or pterostilbene.
- the methods promote wellness by promoting stem cell health and function; such stem cells may be intestinal, skin, muscle, hematopoietic, or neural stem cells.
- the methods may also promote wellness by preventing hearing loss or hair loss.
- the methods may promote healthy hair and nail growth.
- the methods may promote muscle building for endurance and strength, weight loss, or and increased immune response (innate and adaptive function).
- compositions disclosed herein may be varied so as to obtain an amount of nicotinamide riboside (compound 4) and/or pterostilbene that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- compound 4 nicotinamide riboside
- pterostilbene pterostilbene
- administration of the composition comprises administration of the composition in one or more dose(s). In some embodiments, administration of the composition comprises administration of the composition in one or more, five or more, ten or more, twenty or more, thirty or more, forty or more, fifty or more, one hundred or more, or one thousand or more dose(s).
- the dose comprises at least 25 mg, at least 50 mg, at least 75 mg, at least 100 mg, at least 125 mg, at least 150 mg, at least 200 mg, at least 225 mg, at least 250 mg, at least 275 mg, at least 300 mg, at least 325 mg, at least 350 mg, at least 375 mg, at least 400 mg, at least 425 mg, at least 450 mg, at least 475 mg, at least 500 mg, at least 550 mg, at least 600 mg, at least 650 mg, at least 700 mg, at least 750 mg, at least 800 mg, or at least 850 mg of nicotinamide riboside (compound 4).
- the dose comprises at least 5 mg, at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg, at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least 60 mg, at least 65 mg, at least 70 mg, at least 75 mg, at least 80 mg, at least 90 mg, at least 95 mg, at least 100 mg, at least 110 mg, at least 120 mg, at least 130 mg, at least 140 mg, at least 150 mg, at least 160 mg, least 170 mg, at least 180 mg, at least 190 mg, at least 200 mg, or at least 250 mg of pterostilbene.
- compositions disclosed herein may be administered over any period of time effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- the period of time may be at least 1 day, at least 10 days, at least 20 days, at least 30, days, at least 60 days, at least three months, at least six months, at least a year, at least three years, at least five years, or at least ten years.
- the dose may be administered when needed, sporadically, or at regular intervals. For example, the dose may be administered monthly, weekly, biweekly, triweekly, once a day, or twice a day.
- compound 4 alone or in combination with pterostilbene, may be formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents.
- the agents described herein can be administered as such, or administered in mixtures with pharmaceutically acceptable carriers and can also be administered in conjunction with other agents.
- Conjunctive therapy thus includes sequential, simultaneous and separate, or co-administration of one or more compounds of the invention, wherein the therapeutic effects of the first administered has not entirely disappeared when the subsequent compound is administered.
- compositions useful for the methods of the invention are described above.
- Molar equivalents of nicotinamide are minimized in the range of 1.0 to 1.1 as the nicotinamide hydrochloride (byproduct) is difficult to remove.
- Acetyl chloride can be added as a drying agent.
- thionyl chloride was less reactive as compared to HCl and has the disadvantage of generating sulfur containing byproducts.
- MTBE methyl tert butyl ether
- Nicotinamide riboside triacetate 1000 2.40 Methanol 5000 5.00 7M Methanolic NH 3 1700 5.00 Procedure: Methanolic NH 3 is added to nicotinamide riboside triacetate and kept for 16 hour at ⁇ 10 to ⁇ 5° C. Methanol was added to the crude and co-distilled. Solids were filtered and washed with methanol and acetone. Off white product was formed with 68% yield.
- Nicotinamide (253.8 g; 1.1 equiv) was charged to the reactor, resulting in a white suspension which exothermed to 26° C.
- Acetonitrile (474.0 g) was added to the reactor.
- the reactor contents were adjusted to 15° C. and tributylamine (384.4 g, 1.1 equiv) was charged over not less than 20 min followed by an acetonitrile rinse (57 g). A moderate exotherm was observed (max 24° C.).
- the reactor contents were adjusted to 25° C. and agitated for 18 h.
- An IPC sample for reaction completion indicated 38 A % Nicotinamide (IPC specification: not more than 50% Nicotinamide at 260 nm). No change was seen after 31 h.
- Step 3 Supplemental Tributylamine Charge (Due to Overcharge of HCl Gas)
- the pale yellow slurry was chilled to 0° C. (0 to 5° C.) and vacuum filtered through centrifuge cloth (20-25 m pore size).
- Acetone (1200 g or 948 g) was charged to the empty reactor and cooled to 0-1° C. with stirring to mobilize product residue. After complete deliquoring in the filter, the product cake was washed with the chilled acetone.
- the product was dried under vacuum for 24 h at 40-45° C. to afford NR-A (378.65 g (48.2% yield)) as white chalky solids (2.0 A % Nicotinamide, 97.4 A % NR-A (260 nm), 0.13 A % Anomer).
- Product was 100 A % via CAD Detector. Moisture Balance: 0.26% wt loss (75° C., 30 min).
- a 5 L jacketed reactor was charged with methanol (350 g).
- NR-A (350 g) was charged to reactor at 22° C. to give a stirred suspension followed by methanol (350 g) rinse.
- the reactor contents were cooled to below ⁇ 5 to ⁇ 3° C. and diethylamine (49.35 g, 0.8 equiv) was charged to the suspension maintaining not more than 1° C. followed by methanol (133 g) rinse.
- the reaction mixture was stirred at ⁇ 3° C. for not less than 2 hours and the suspension became a tea colored solution (at plant-scale a polish filtration may be performed).
- the reaction was left to stir for 19 h at ⁇ 3° C.
- the resulting thick pale yellow suspension was vacuum filtered through centrifuge cloth (20-m pore size) at not more than 0-5° C.
- Ethanol SDA-3C was charged to the reactor (553 g, 700 mL) and cooled to 0-5° C. The contents were used to rinse the product cake.
- Acetone (549 g, 700 mL) was charged to the reactor and the contents were cooled to below 0° C. The contents were used to rinse the product cake.
- MTBE 518.0 g, 700 mL was charged to the reactor and the contents were cooled to below 0° C. The contents were used to rinse the product cake.
- the product was dried under vacuum for 24 h at 30-40° C.
- NR-B 126.9 g (52% yield)
- NR-B 126.9 g (52% yield)
- Moisture Balance 0.56% wt loss (75° C., 30 min).
- Percent product loss to filtrate 43.7 g NR-B, 17.9% of theory.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
- This application is a divisional application of U.S. patent application Ser. No. 16/627,583, filed Dec. 30, 2019, which is a § 371 national-stage application based on PCT/US2018/40228, filed Jun. 29, 2018, which claims the benefit of priority to U.S. Provisional Patent Application Ser. No. 62/527,382, filed Jun. 30, 2017, each of which is hereby incorporated by reference in its entirety.
- Nicotinamide riboside is a pyridine-nucleoside form of niacin (i.e., vitamin B3) that serves as a precursor to nicotinamide adenine dinucleotide (NAD+). NAD+ promotes cellular metabolism, mitochondrial function, and energy production. Currently, nicotinamide riboside is made through synthetic methods or fermentation processes. Because of its significant potential to confer health benefits when used as a dietary supplement, there exists a need to develop highly efficient and scalable processes for the manufacture of nicotinamide riboside.
- In some aspects, the present invention provides a method of preparing compound 3,
- comprising the steps of:
-
- (a) combining compound 1 and a chlorinating agent, thereby producing a first reaction mixture comprising compound 2, wherein:
- compound 1 is represented by
- (a) combining compound 1 and a chlorinating agent, thereby producing a first reaction mixture comprising compound 2, wherein:
-
-
- compound 2 is represented by
-
- and the chlorinating agent is gaseous HCl or HCl in dioxane;
-
- (b) combining compound 2 with nicotinamide, thereby producing a second reaction mixture comprising compound 3.
- In further aspects, the present invention provides a method of preparing compound 4, comprising the steps of:
-
- (c) combining compound 3 with an ammonia reagent, thereby producing a first reaction mixture comprising compound 4, wherein:
compound 3 is represented by
- (c) combining compound 3 with an ammonia reagent, thereby producing a first reaction mixture comprising compound 4, wherein:
- and the ammonia reagent is methanolic ammonia or diethylamine.
- In further embodiments, the invention provides a compound having the structure of Compound 4, made according to method described herein.
- In certain aspects, the present invention provides a method of improving cellular health in a subject, comprising administering to the subject a compound having the structure of Compound 4, made according to method described herein.
- In certain aspects, the present invention provides a method of improving sleep quality, stimulating or increasing REM sleep, or treating or preventing insomnia, desynchronosis, or a circadian rhythm sleep disorder in a subject, comprising administering to the subject a compound having the structure of Compound 4, made according to method described herein.
- In certain aspects, the present invention provides a method of treating or preventing a motor neuron disease or ALS, or slowing or reversing the progression of motor neuron degeneration in a subject, comprising administering to the subject a compound having the structure of Compound 4, made according to method described herein.
- In certain aspects, the present invention provides a method of improving fertility, treating or preventing infertility, inducing ovulation, increasing sperm count, or increasing lactation, comprising administering to the subject a compound having the structure of Compound 4, made according to method described herein.
- In certain aspects, the present invention provides a method of treating or preventing kidney damage, acute kidney injury, or kidney disease, or increasing blood flow to the kidneys, comprising administering to the subject a compound having the structure of Compound 4, made according to method described herein.
- In certain aspects, the present invention provides a method of treating or preventing liver damage or fatty liver, or decreasing the serum level of alanine transaminase (ALT) or aspartate transaminase (AST) in a subject, comprising administering to the subject a compound having the structure of Compound 4, made according to method described herein.
- The term “acyl” is art-recognized and refers to a group represented by the general formula hydrocarbyl-C(O)—, preferably alkyl-C(O)—.
- The term “acetyl” refers to a specific acyl group having the formula H3C—C(O)—. Acetyl may be abbreviated as “Ac—.”
- An “alkyl” group or “alkane” is a straight chained or branched non-aromatic hydrocarbon which is completely saturated. Typically, a straight chained or branched alkyl group has from 1 to about 20 carbon atoms, preferably from 1 to about 10, or 1 to 6, unless otherwise defined. Examples of straight chained and branched alkyl groups include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, tert-butyl, pentyl, hexyl, pentyl and octyl. A C1-C6 straight chained or branched alkyl group is also referred to as a “lower alkyl” group.
- The term “Cx-y” when used in conjunction with a chemical moiety, such as alkyl is meant to include groups that contain from x to y carbons in the chain. For example, the term “Cx-yalkyl” refers to substituted or unsubstituted saturated hydrocarbon groups, including straight-chain alkyl and branched-chain alkyl groups that contain from x to y carbons in the chain, including haloalkyl groups such as trifluoromethyl and 2,2,2-tirfluoroethyl, etc. C0 alkyl indicates a hydrogen where the group is in a terminal position, a bond if internal. The terms “C2-yalkenyl” and “C2-yalkynyl” refer to substituted or unsubstituted unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond respectively.
- A “trialkylamine” means a compound having the structure N(R1)(R2)(R3), wherein R1, R2, and R3 are each an alkyl group, and can be identical or different. Exemplary trialkylamine compounds include trimethylamine, trimethylamine, triisopropylamine, tributylamine, and isopropyldimethylamine.
- As used herein, the term “chlorinating agent” means a reagent that provides a source of chlorine anions (i.e., Cl−). Exemplary chlorinating agents include sources of HCl, such as HCl gas or HCl in a solvent such as ethanol or dioxane. For example, a chlorinating agent used in the methods of the invention is preferably HCl in dioxane. An alternative chlorinating agent that is preferably used in some embodiments of the methods of the invention is gaseous HCl (i.e., HCl (gas)).
- Nicotinamide is a molecule having the following structure:
- As used herein, the term “ammonia reagent” means a reagent that provides a source of ammonia (i.e., NH3), or an alkyl amine (such as methylamine), or a dialkylamine (such as diethylamine), or an alkylenediamine (such as ethylenediamine). Ammonia may be supplied as a gas (i.e., NH3 (g)) or in a solution of an organic solvent, such as methanol, ethanol, isopropanol, dioxane, or tetrahydrofuran (THF). In some embodiments, the term “ammonia reagent” also includes ammonia supplied in aqueous solution.
- In describing a process of filtration, the liquid material that passes through the filter is referred to herein as the “filtrate”. The solid material that collects (i.e., is filtered from the filtrate), is referred to herein as the “retentate.” As used herein, the term “administering” means providing a pharmaceutical agent or composition to a subject, and includes, but is not limited to, administering by a medical professional and self-administering. Administration of a substance, a compound or an agent to a subject can be carried out using one of a variety of methods known to those skilled in the art. For example, a compound or an agent can be administered, intravenously, arterially, intradermally, intramuscularly, intraperitoneally, subcutaneously, ocularly, sublingually, orally (by ingestion), intranasally (by inhalation), intraspinally, intracerebrally, and transdermally (by absorption, e.g., through a skin duct). A compound or agent can also appropriately be introduced by rechargeable or biodegradable polymeric devices or other devices, e.g., patches and pumps, or formulations, which provide for the extended, slow or controlled release of the compound or agent. Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods.
- Appropriate methods of administering a substance, a compound or an agent to a subject will also depend, for example, on the age and/or the physical condition of the subject and the chemical and biological properties of the compound or agent (e.g., solubility, digestibility, bioavailability, stability and toxicity). In some embodiments, a compound or an agent is administered orally, e.g., to a subject by ingestion. In some embodiments, the orally administered compound or agent is in an extended release or slow release formulation, or administered using a device for such slow or extended release.
- The phrase “pharmaceutically-acceptable carrier” as used herein means a pharmaceutically-acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material.
- As used herein, the term “subject” means a human or non-human animal selected for treatment or therapy.
- The phrases “therapeutically-effective amount” and “effective amount” as used herein means the amount of an agent which is effective for producing the desired therapeutic effect in at least a sub-population of cells in a subject at a reasonable benefit/risk ratio applicable to any medical treatment.
- “Treating” a disease in a subject or “treating” a subject having a disease refers to subjecting the subject to a pharmaceutical treatment, e.g., the administration of a drug, such that at least one symptom of the disease is decreased or prevented from worsening.
- As used herein, a therapeutic that “prevents” a disorder or condition refers to a compound that, when administered to a statistical sample prior to the onset of the disorder or condition, reduces the occurrence of the disorder or condition in the treated sample relative to an untreated control sample, or delays the onset or reduces the severity of one or more symptoms of the disorder or condition relative to the untreated control sample.
- This invention is based on the discovery of an efficient, scalable synthesis of nicotinamide riboside.
- In certain aspects, the present invention provides a method for preparing compound 3,
- comprising the steps of:
-
- (a) combining compound 1 and a chlorinating agent, thereby producing a first reaction mixture comprising compound 2, wherein:
- compound 1 is represented by
- (a) combining compound 1 and a chlorinating agent, thereby producing a first reaction mixture comprising compound 2, wherein:
-
-
- compound 2 is represented by
-
- and the chlorinating agent is gaseous HCl or HCl in dioxane; and
-
- (b) combining compound 2 with nicotinamide, thereby producing a second reaction mixture comprising compound 3.
- In certain embodiments, the chlorinating agent is gaseous HCl (i.e., HCl (g)). Alternatively, in some embodiments, the chlorinating agent is HCl in dioxane.
- In certain embodiments, step (a) occurs in a first solvent. The first solvent may be combined with compound 1 (i.e., a solution of compound 1 in the first solvent may be produced) prior to combination of compound 1 with the chlorinating agent. Alternatively, the first solvent, compound 1, and the chlorinating agent may be combined together simultaneously. In another alternative, the first solvent and the chlorinating agent may be combined first, followed by combination of that mixture with compound 1.
- In some embodiments, the first solvent is a component of the chlorinating agent. For example, in certain embodiments the chlorinating agent is HCl in dioxane. In certain such embodiments, dioxane is the first solvent.
- In certain embodiments, the chlorinating agent is HCl in dioxane and the first solvent is dioxane. In alternative embodiments, the chlorinating agent is HCl in dioxane and the first solvent is dichloromethane (DCM).
- Alternatively, in methods in which the chlorinating agent is gaseous HCl, the first solvent may be acetonitrile.
- In certain embodiments, step (a) further comprises acetyl chloride (AcCl).
- Step (a) may be monitored by any reaction monitoring mechanism employed by persons of ordinary skill in the art, including thin layer chromatography, nuclear magnetic resonance spectroscopy, mass spectroscopy, and high performance liquid chromatography.
- Upon completion of step (a), the reaction mixture may be concentrated to remove or reduce the amounts of HCl and excess solvent present in the reaction mixture. In some embodiments, such a concentration step affords a concentrated crude material comprising compound 2.
- Thus, in certain embodiments, the method further comprises step (a′):
-
- (a′) concentrating the first reaction mixture under reduced atmospheric pressure; wherein step (a′) occurs after step (a) and before step (b).
- Upon completion of steps (a) and (a′), a concentrated crude material comprising compound 2 is afforded.
- In certain embodiments, the methods of the invention further comprise combining compound 2 and a second solvent. For example, the concentrated crude material comprising compound 2 yielded from steps (a) and (a′) may be combined with a second solvent.
- In certain embodiments, the second solvent is acetonitrile.
- In certain embodiments, step (b) occurs in a second solvent. The second solvent may be a polar aprotic solvent. For example, the second solvent may be acetonitrile.
- In certain embodiments, the method further comprises step (b′):
-
- (b′) combining the second reaction mixture with a trialkylamine;
- wherein step (b′) occurs after step (b).
- In certain such embodiments, the trialkylamine is tributylamine.
- In certain embodiments, following step (b′), the resultant reaction mixture comprising compound 3 is filtered, and the solids (i.e., retentate) are washed. The retentate comprises compound 3. The retentate may be washed with a cold solvent, such as cold acetonitrile or cold methanol.
- In certain embodiments, the method further comprises step (c):
-
- (c) combining compound 3 with an ammonia reagent, thereby producing a third reaction mixture comprising compound 4, wherein: compound 4 is represented by
- and the ammonia reagent is methanolic ammonia or diethylamine.
- In certain embodiments, the ammonia reagent is diethylamine.
- In certain embodiments, the ammonia reagent is methanolic ammonia.
- In certain embodiments, the methanolic ammonia is 1M, 2M, 3M, 4M, 5M, 6M, 7M, 8M, 9M, or 10M methanolic ammonia. Preferably, the methanoic ammonia is 7M methanolic ammonia.
- In certain embodiments, step (c) occurs in a third solvent. The third solvent may be a polar protic solvent, such as an alcohol. The third solvent may, for example, be methanol, ethanol, isopropanol, or butanol. In certain preferred embodiments, the third solvent is methanol.
- In certain embodiments, step (c) takes place at a temperature below room temperature.
- In further embodiments wherein the ammonia reagent is diethylamine, the method of the invention further comprises step (c′), which occurs after step (c):
-
- (c′) adding cold aqueous HCl to the third reaction mixture, thereby producing a fourth mixture comprising compound 4.
- In further embodiments wherein the ammonia reagent is methanolic ammonia, the method of the invention further comprises step (c′), which occurs after step (c):
-
- (c′) concentrating the third reaction mixture under reduced atmospheric pressure, thereby producing a fourth mixture comprising compound 4.
- In certain embodiments, the method of the invention further comprises step (c″), which occurs after step (c′):
-
- (c″) filtering the fourth mixture.
- In certain such embodiments, the method further comprises rinsing the resultant retentate (i.e., the solids left behind after filtration) with cold methanol or ethanol.
- In other certain such embodiments, the method further comprises rinsing the resultant retentate (i.e., the solids left behind after filtration) with cold acetone.
- In yet other certain such embodiments, the method further comprises rinsing the resultant retentate (i.e., the solids left behind after filtration) with cold methyl tert butyl ether (MTBE).
- In certain embodiments, the reaction between the ammonia reagent and compound 3 may be monitored by any reaction monitoring mechanism employed by persons of ordinary skill in the art. Upon completion or significant progression of this reaction (i.e., upon formation of compound 4), the reaction mixture may be distilled, for example to remove the ammonia reagent and the third solvent. In certain such embodiments, compound 4 remains in the distillation pot. In further such embodiments, the remaining contents of the distillation may then by filtered and washed. In certain embodiments, the washing liquid is cold acetone and/or cold methanol.
- In further embodiments, the invention provides a method of preparing compound 4,
- comprising the steps of:
-
- (c) combining compound 3 with an ammonia reagent, thereby producing a first reaction mixture comprising compound 4, wherein:
- compound 3 is represented b
- (c) combining compound 3 with an ammonia reagent, thereby producing a first reaction mixture comprising compound 4, wherein:
- and the ammonia reagent is methanolic ammonia or diethylamine.
- In certain embodiments, the ammonia reagent is diethylamine.
- In certain embodiments, the ammonia reagent is methanolic ammonia.
- In certain embodiments, the methanolic ammonia is 1M, 2M, 3M, 4M, 5M, 6M, 7M, 8M, 9M, or 10M methanolic ammonia. Preferably, the methanoic ammonia is 7M methanolic ammonia.
- In certain embodiments, step (c) occurs in a third solvent. The third solvent may be a polar protic solvent, such as an alcohol. The third solvent may, for example, be methanol, ethanol, isopropanol, or butanol. In certain preferred embodiments, the third solvent is methanol.
- In certain embodiments, step (c) takes place at a temperature below room temperature.
- In further embodiments wherein the ammonia reagent is diethylamine, the method of the invention further comprises step (c′), which occurs after step (c):
-
- (c′) adding cold aqueous HCl to the third reaction mixture, thereby producing a fourth mixture comprising compound 4.
- In further embodiments wherein the ammonia reagent is methanolic ammonia, the method of the invention further comprises step (c′), which occurs after step (c):
-
- (c′) concentrating the third reaction mixture under reduced atmospheric pressure, thereby producing a fourth mixture comprising compound 4.
- In certain embodiments, the method of the invention further comprises step (c″), which occurs after step (c′):
-
- (c″) filtering the fourth mixture.
- In certain such embodiments, the method further comprises rinsing the resultant retentate (i.e., the solids left behind after filtration) with cold methanol or ethanol.
- In other certain such embodiments, the method further comprises rinsing the resultant retentate (i.e., the solids left behind after filtration) with cold acetone.
- In yet other certain such embodiments, the method further comprises rinsing the resultant retentate (i.e., the solids left behind after filtration) with cold methyl tert butyl ether (MTBE).
- In certain embodiments, the method further comprises:
-
- (a) combining compound 1 and a chlorinating agent, thereby producing a first reaction mixture comprising compound 2, wherein:
- compound 1 is represented by
- (a) combining compound 1 and a chlorinating agent, thereby producing a first reaction mixture comprising compound 2, wherein:
-
-
- compound 2 is represented by
-
- and the chlorinating agent is gaseous HCl or HCl in dioxane; and
-
- (b) combining compound 2 with nicotinamide, thereby producing a second reaction mixture comprising compound 3.
- In certain embodiments, the chlorinating agent is gaseous HCl (i.e., HCl (g)). Alternatively, in some embodiments, the chlorinating agent is HCl in dioxane.
- In certain embodiments, step (a) occurs in a first solvent. The first solvent may be combined with compound 1 (i.e., a solution of compound 1 in the first solvent may be produced) prior to combination of compound 1 with the chlorinating agent. Alternatively, the first solvent, compound 1, and the chlorinating agent may be combined together simultaneously. In another alternative, the first solvent and the chlorinating agent may be combined first, followed by combination of that mixture with compound 1.
- In some embodiments, the first solvent is a component of the chlorinating agent. For example, in certain embodiments the chlorinating agent is HCl in dioxane. In certain such embodiments, dioxane is the first solvent.
- In certain embodiments, the chlorinating agent is HCl in dioxane and the first solvent is dioxane. In alternative embodiments, the chlorinating agent is HCl in dioxane and the first solvent is dichloromethane (DCM).
- Alternatively, in methods in which the chlorinating agent is gaseous HCl, the first solvent may be acetonitrile.
- In certain embodiments, step (a) further comprises acetyl chloride (AcCl).
- Step (a) may be monitored by any reaction monitoring mechanism employed by persons of ordinary skill in the art, including thin layer chromatography, nuclear magnetic resonance spectroscopy, mass spectroscopy, and high pressure liquid chromatography.
- Upon completion of step (a), the reaction mixture may be concentrated to remove or reduce the amounts of HCl and excess solvent present in the reaction mixture. In some embodiments, such a concentration step affords a concentrated crude material comprising compound 2.
- Thus, in certain embodiments, the method further comprises step (a′):
-
- (a′) concentrating the first reaction mixture under reduced atmospheric pressure; wherein step (a′) occurs after step (a) and before step (b).
- Upon completion of steps (a) and (a′), a concentrated crude material comprising compound 2 is afforded.
- In certain embodiments, the methods of the invention further comprise combining compound 2 and a second solvent. For example, the concentrated crude material comprising compound 2 yielded from steps (a) and (a′) may be combined with a second solvent.
- In certain embodiments, the second solvent is acetonitrile.
- In certain embodiments, step (b) occurs in a second solvent. The second solvent may be a polar aprotic solvent. For example, the second solvent may be acetonitrile.
- In certain embodiments, the method further comprises step (b′):
-
- (b′) combining the second reaction mixture with a trialkylamine;
- wherein step (b′) occurs after step (b).
- In certain such embodiments, the trialkylamine is tributylamine.
- In certain embodiments, following step (b′), the resultant reaction mixture comprising compound 3 is filtered, and the solids (i.e., retentate) are washed. The retentate comprises compound 3. The retentate may be washed with a cold solvent, such as cold acetonitrile or cold methanol.
- A “polar protic solvent” as used herein is a solvent having a dipole moment of about 1.4 to 4.0 D, and comprising a chemical moiety that participates in hydrogen bonding, such as an O—H bond or an N—H bond. Exemplary polar protic solvents include methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, ammonia, water, and acetic acid.
- A “polar aprotic solvent” as used herein means a solvent having a dipole moment of about 1.4 to 4.0 D that lacks a hydrogen bonding group such as O—H or N—H. Exemplary polar aprotic solvents include acetone, N,N-dimethylformamide, acetonitrile, ethyl acetate, dichloromethane, tetrahydrofuran, and dimethylsulfoxide.
- A “non-polar solvent” as used herein means a solvent having a low dialectric constant (<5) and low dipole moment of about 0.0 to about 1.2. Exemplary nonpolar solvents include pentane, hexane, cyclohexane, benzene, toluene, chloroform, and diethyl ether.
- For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 67th Ed., 1986-87, inside cover.
- Examples of alcohols include, without limitation, methanol, ethanol, 2-butoxyethanol, propanol, allyl alcohol, methallyl alcohol, prenol, isopropanol, 2,2-dimethylpropan-1-ol, 2-methyl-2-phenylpropan-1-ol, butanol, isobutanol, sec-butanol, tert-butanol, 2-buten-1-ol, pentanol, 2-cyclopenten-1-ol, 4-cyclopenten-1-ol, cyclopentanol, 3-cyclopenten-1-ol, hexanol, cyclohexanol, 3-cyclohexen-1-ol, phenol, 1-naphthol, 2-naphthol, benzyl alcohol, menthol, 1,2-ethanediol, 9-fluorenylmethanol, resorcinol, meta-cresol, cinnamyl alcohol, and geraniol.
- In certain embodiments, the invention provides Compound 4, made according to any of the methods of preparation described herein.
- In certain embodiments, compound 4 is produced in a yield of about 30%, about 32%, about 34%, about 36%, about 38%, about 40%, about 42%, about 44%, about 46%, about 48%, about 50% or higher from compound 1.
- In certain embodiments, the purity of the compound is 95%, 96%, 97%, 98%, 99%, 99.2%, 99.4%, 99.6%, 99.8% or higher.
- As described in detail below, the pharmaceutical compositions described herein may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; or (3) sublingually.
- In some embodiments, the composition comprises additional agents. For example, the composition may comprise a nutritional agent, such as an antioxidant. Examples of pharmaceutically-acceptable antioxidants include: (1) water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.
- The formulations of the compounds described herein may be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated and the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the agent which produces a therapeutic effect.
- In certain embodiments, a formulation described herein comprises an excipient, including, but not limited to, cyclodextrins, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and polyanhydrides; and an agent of the invention. In some embodiments, an aforementioned formulation renders orally bioavailable an agent of the invention. Methods of preparing these formulations or compositions may include the step of bringing into association a compound of the invention with the carrier and, optionally, one or more accessory ingredients.
- Liquid dosage forms for oral administration of the formulations provided herein include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
- Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.
- Formulations provided herein suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and/or as mouth washes and the like, each containing a predetermined amount of a compound of the invention as an active ingredient. A compound of the invention may also be administered as a bolus, electuary, or paste.
- In solid dosage forms of the invention for oral administration (e.g., capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and/or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and/or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for example, cetyl alcohol, glycerol monostearate, and non-ionic surfactants; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
- A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- The tablets, and other solid dosage forms of the pharmaceutical compositions described herein, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and/or microspheres. Compositions described herein may also be formulated for rapid release, e.g., freeze-dried. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.
- Pharmaceutical compositions provided herein suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
- Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- In certain embodiments, the present invention provides a method of improving cellular health in a subject, comprising administering to the subject a compound made by the synthetic methods disclosed herein.
- In further embodiments, the present invention provides methods for:
-
- improving sleep quality;
- stimulating or increasing REM sleep;
- treating or preventing insomnia;
- treating or preventing desynchronosis; or
- treating or preventing a circadian rhythm sleep disorder in a subject, comprising administering to the subject Compound 4 prepared by the synthetic methods disclosed herein.
- In certain embodiments, such a method of treatment further comprises administering pterostilbene.
- In some embodiments, the methods treat or prevent a circadian rhythm sleep disorder. The circadian rhythm sleep disorder can be extrinsic (e.g., shift work sleep disorder, desynchornosis) or intrinsic (e.g., advanced sleep phase disorder (ASPD), delayed sleep phase disorder (DSPD), irregular sleep-wake rhythm, and/or non-24-hour sleep-wake disorder (i.e., hypernychthemeral syndrome)).
- The subject may be male or female. In some embodiments, the subject is an adult (i.e., 18 years of age or older). The subject may be pediatric (i.e., less than 18 years of age). In some embodiments, the subject is a mammal, preferably, a human.
- In certain aspects, the methods and compositions provided herein relate to improving sleep health and the quality of sleep in a subject in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside (compound 4) and/or pterostilbene. Sleep quality may refer to the “restfulness” of sleep (i.e., how rested an individual feels during waking hours). Sleep quality may refer to the quantity of sleep. Good sleep quality is associated with a wide range of positive outcomes such as better health, less daytime sleepiness, greater well-being and better psychological functioning. In some embodiments, a subject has a score of 1, 2, or 3 on the Pittsburgh Sleep Quality Index (PSQI). Further details on the PSQI may be found at Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989). The Pittsburgh Sleep Quality Index (PSQI): A new instrument for psychiatric research and practice. Psychiatry Research, 28(2), 193-213, incorporated herein by reference in its entirety. In some embodiments, the subject has trouble falling asleep. In some embodiments, the subject has trouble staying asleep. In some embodiments, the subject wakes in the morning at an hour that would disrupt a normal sleep cycle or otherwise affect sleep quality.
- In some aspects, provided herein are methods of stimulating REM sleep in need thereof, comprising administering to the subject a composition comprising nicotinamide riboside (compound 4) and/or pterostilbene. Rapid eye movement sleep (REM sleep) is a unique phase of sleep characterized by rapid movement of the eyes, low muscle tone throughout the body, and the propensity of the sleeper to dream vividly. In some embodiments, the compositions and methods disclosed herein increase the total amount of time a subject is in REM sleep per sleep session (e.g., the total amount of time in REM per night). In some embodiments, the compositions and methods disclosed herein increase the amount of time a subject is in REM sleep per sleep cycle. Sleep progresses in a series of four or five more or less regular sleep cycles of non-REM and REM sleep throughout the night. The first sleep cycle is typically around 90 minutes in length, with the succeeding cycles averaging around 100-120 minutes, although some individuals may have longer or shorter average cycles. Each cycle follows the stages of non-REM sleep (stage 1-stage 2-stage 3) and then, after a period in deep stage 3 slow-wave sleep, back through the stages (stage 3-stage 2-stage 1). Then, instead of waking, the sleeper may enter a short period of REM sleep, before going back through non-REM stages in a new cycle. As the night progresses, the time spent in deep stage 3 sleep decreases and the time spent in REM sleep increases, so that there is a greater proportion of stage 3 sleep earlier in the night, and a greater proportion of REM sleep later in the night, particularly during the final two sleep cycles. As used herein, stimulating REM or increasing REM may refer to increasing the time a subject stays in REM sleep per sleep cycle or the total amount of time a subject is sleeping per day.
- In certain aspects, the methods and compositions provided herein relate to the treatment and/or prevention of sleep disorders in a subject by administering to the subject (e.g., orally administering to the subject) a composition comprising nicotinamide riboside (compound 4) and/or pterostilbene.
- In some embodiments, the subject has insomnia. Insomnia is a sleep disorder that is characterized by the inability to sleep. For example, a subject with insomnia may have trouble falling asleep, staying asleep, or wake up too early and not be able to get back to sleep. As used herein, insomnia may refer to short-term (acute) insomnia (i.e., the inability to sleep that lasts for days to weeks) or long-term (chronic) insomnia (i.e., the inability to sleep for one month or more). In some embodiments, the insomnia is transient insomnia. Insomnia may be the result of stress, a traumatic event, nasal/sinus allergies, gastrointestinal problems, brain lesions and tumors, stroke, chronic pain, chronic fatigue syndrome, congestive heart failure, angina, acid-reflux disease (GERD), chronic obstructive pulmonary disease, asthma, endocrine disorders such as hyperthyroidism, arthritis, neurological conditions such as Parkinson's or Alzheimer's disease, low back pain, or genetics. In some embodiments, the subject has restless leg syndrome. In some embodiments, the subject has sleep apnea. In some embodiments, the subject has a psychological condition that interferes with sleep, such as anxiety, depression, bipolar disorder, schizophrenia, posttraumatic stress disorder (PTSD), and/or attention deficit hyperactivity disorder (ADHD). In some embodiments, insomnia is a side effect of medication. Examples of medications that may cause insomnia include, but are not limited to, corticosteroids, alpha blockers, beta blockers, SSRI antidepressants, ACE inhibitors, cholinesterase inhibitors, second generation (non-sedating) H1 agonists, or glucosamine/chondroitin.
- Provided herein are methods and compositions useful in regulating a subject's circadian rhythm. Circadian rhythms regulate the timing of periods of sleepiness and wakefulness throughout the day. Circadian rhythms are endogenously generated, although they can be modulated by external cues such as sunlight and temperature. Circadian rhythms are important in determining the sleeping and feeding patterns of all animals, including human beings. There are clear patterns of brain wave activity, hormone production, cell regeneration and other biological activities linked to this daily cycle, and an irregular circadian rhythm may lead to a disturbance any of the previously mentioned processes. In some embodiments, the subject has a circadian rhythm sleep disorder. The circadian rhythm sleep disorder may be extrinsic (e.g., the result of environmental influences or circumstances) or intrinsic (e.g., the result of genetics or not the result of circumstances). An example of an extrinsic circadian sleep disorder includes shift work sleep disorder, which often affects individuals who work nights or in rotating shifts. Intrinsic sleep disorders include advanced sleep phase disorder (ASPD), delayed sleep phase disorder (DSPD), irregular sleep-wake rhythm, and/or non-24-hour sleep-wake disorder (i.e., hypernychthemeral syndrome)). ASPD is characterized by difficulty staying awake in the evening and difficulty staying asleep in the morning. DSPD is characterized by a much later than normal timing of sleep onset and offset and a period of peak alertness in the middle of the night. Individuals with irregular sleep-wake rhythm suffer from sleeping at very irregular times, and usually more than twice per day (waking frequently during the night and taking naps during the day), but often sleep a normal period of total time per day typical for the person's age. Non-24-hour sleep-wake disorder, or hypernychthemeral syndrome, is a sleep disorder wherein the affected individual's sleep occurs later and later each day, with the period of peak alertness also continuously moving around the clock from day to day.
- In some aspects, the compositions and methods provided herein are useful in treating desynchronosis (i.e., jet lag). Jet lag is a temporary sleep disorder caused by crossing time zones (e.g., during an airplane flight), and is often the result of disruption to the circadian rhythms of the body. Jet lag may occur any time the body's internal clock is out of sync with cues from a new time zone. Cues can include light exposure and eating times. General symptoms include fatigue and disorientation, interrupted sleep, confusion, mood changes, and pain in limbs.
- Actual dosage levels and administration regimen of the compositions disclosed herein may be varied so as to obtain an amount of nicotinamide riboside and/or pterostilbene that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. In some embodiments, the subject continuously self-administers the compounds disclosed herein. In other embodiments, the subject may take a compound disclosed herein as needed.
- In some embodiments, administration of the composition comprises administration of the composition in one or more dose(s). In some embodiments, administration of the composition comprises administration of the composition in one or more, five or more, ten or more, twenty or more, thirty or more, forty or more, fifty or more, one hundred or more, or one thousand or more dose(s). In some embodiments, the dose comprises at least 25 mg, at least 50 mg, at least 75 mg, at least 100 mg, at least 125 mg, at least 150 mg, at least 200 mg, at least 225 mg, at least 250 mg, at least 275 mg, at least 300 mg, at least 325 mg, at least 350 mg, at least 375 mg, at least 400 mg, at least 425 mg, at least 450 mg, at least 475 mg, at least 500 mg, at least 550 mg, at least 600 mg, at least 650 mg, at least 700 mg, at least 750 mg, at least 800 mg, or at least 850 mg nicotinamide riboside (compound 4). In some embodiments, the dose comprises at least 5 mg, at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg, at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least 60 mg, at least 65 mg, at least 70 mg, at least 75 mg, at least 80 mg, at least 90 mg, at least 95 mg, at least 100 mg, at least 110 mg, at least 120 mg, at least 130 mg, at least 140 mg, at least 150 mg, at least 160 mg, least 170 mg, at least 180 mg, at least 190 mg, at least 200 mg, or at least 250 mg of pterostilbene.
- The compositions disclosed herein may be administered over any period of time effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The period of time may be at least 1 day, at least 10 days, at least 20 days, at least 30, days, at least 60 days, at least three months, at least six months, at least a year, at least three years, at least five years, or at least ten years. The dose may be administered when needed, sporadically, or at regular intervals. For example, the dose may be administered monthly, weekly, biweekly, triweekly, once a day, or twice a day.
- In further embodiments, the present invention provides methods of:
-
- treating or preventing a motor neuron disease;
- treating or preventing ALS; or
- slowing or reversing the progression of motor neuron degeneration in a subject, comprising administering to the subject Compound 4 prepared by the synthetic methods disclosed herein.
- In certain embodiments, such a method of treatment further comprises administering pterostilbene.
- In certain embodiments, the motor neuron disease is ALS, hereditary spastic paraplegia (HSP), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), progressive bulbar palsy (PBP), pseudobulbar palsy, or a spinal muscular atrophy.
- In some embodiments, the subject may have or be predisposed to a motor neuron disease (e.g., amyotrophic lateral sclerosis (ALS), such as medulla ALS or brainstem ALS). A motor neuron disease or disorder may be any disease or disorder that affects the function or structure of motor neuron. As used herein, a motor neuron diseases include progressive diseases that result in loss of function of motor neurons, or nerves, in the brain and spinal cord. Examples of motor neuron diseases include amyotrophic lateral sclerosis (ALS), hereditary spastic paraplegia (HSP), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), progressive bulbar palsy (PBP), pseudobulbar palsy, or a spinal muscular atrophy. A motor neuron disease may affect the upper motor neurons or the lower motor neurons.
- Actual dosage levels and administration regimen of the compositions disclosed herein may be varied so as to obtain an amount of nicotinamide riboside (compound 4) and/or pterostilbene that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- In some embodiments, administration of the composition comprises administration of the composition in one or more dose(s). In some embodiments, administration of the composition comprises administration of the composition in one or more, five or more, ten or more, twenty or more, thirty or more, forty or more, fifty or more, one hundred or more, or one thousand or more dose(s). In some embodiments, the dose comprises at least 100 mg, at least 200 mg, at least 300 mg, at least 400 mg, at least 500 mg, at least 600 mg, at least 700 mg, at least 800 mg, at least 900 mg, at least 1000 mg, at least 1100 mg, at least 1200 mg, at least 1300 mg, at least 1400 mg, at least 1500 mg, at least 1600 mg, at least 1700 mg, at least 1800 mg, at least 1900 mg, at least 2000 mg, at least 2100 mg, at least 2200 mg, at least 2300 mg, at least 2400 mg, at least 2500 mg, at least 2600 mg, at least 2700 mg, at least 2800 mg, at least 2900 mg, or at least 3000 mg, of nicotinamide riboside compound 4). In some embodiments, the dose comprises at least 5 mg, at least 10, at least 20 mg, at least 30 mg, at least 40 mg, at least 50 mg, at least 60 mg, at least 80 mg, at least 100 mg, at least 120 mg, at least 140 mg, at least 160 mg, at least 180 mg, at least 200 mg, at least 220 mg, at least 240 mg, at least 260 mg, at least 280 mg, at least 300 mg, at least 320 mg, at least 340 mg, at least 360 mg, at least 380 mg, at least 400 mg, at least 500 mg, at least 600 mg, at least 700 mg, at least 800 mg, at least 900 mg, or at least 1000 mg of pterostilbene.
- The compositions disclosed herein may be administered over any period of time effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The period of time may be at least 1 day, at least 10 days, at least 20 days, at least 30, days, at least 60 days, at least three months, at least six months, at least a year, at least three years, at least five years, or at least ten years. The dose may be administered when needed, sporadically, or at regular intervals. For example, the dose may be administered monthly, weekly, biweekly, triweekly, once a day, or twice a day.
- In some embodiments, the subject is given a test to measure the general progression or symptomatic progression of a motor neuron disease. In some embodiments, the subject is given a motor function test and/or a cognition and conduct function test. The motor function test may be Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R). The cognition and conduct test may be Complutense Verbal Learning Test (TAVEC), Symbol Digit Modalities Test (SDMT), Verbal Fluency Test, Digit Span (Wechsler Memory Scale III), D2 Attention Test, Wechsler Memory Scale III for Letters and Numbers, London Tower Test, Stroop test, Frontal System Behavior Scale (FrSBe), and/or Brief Test (subjective conduct). In some embodiments, subjects are given both motor function and cognitive function tests. Motor function or cognitive functions tests may be given to the subject once or multiple times.
- In some embodiments, the method further comprises measuring a feature (e.g., a feature associated with inflammation) in the subject. In some embodiments, the feature is measured in a blood test. Examples of features that may be tested are the level of a cytokine, level of amyloid A protein, level of macrophage activation marker neopterin, level of creatine phosphokinase (CPK), level of erythrocyte sedimentation rate, level of C-reactive protein, plasma viscosity, and/or white blood cell count. In some embodiments, the cytokine is proinflammatory cytokine. In some embodiments, the cytokine is an anti-inflammatory cytokine. Examples of cytokines include, but are not limited to, TNFα, IFNγ, IL-1, IL-6, IL-8, or TGFβ.
- In some embodiments, the method further comprises administering a fatty acid supplement to the subject. In some embodiments, the fatty acid supplement comprises an oil. The oil may be processed (e.g., refined, bleached, or deodorized). In other embodiments, the oil is unprocessed or a virgin oil. In some embodiments, the fatty acid supplement is derived or fractionated from a source to yield separated fatty acids. In some embodiments, the oil is a coconut oil. Coconut oil, as used herein, may include any oil produced by the nut of the coconut palm. Fatty acids found in the supplements disclosed herein may be short-chain fatty acids, medium chain fatty acids, or long chain fatty acids. Exemplary fatty acids that may be found in the supplement include, but are not limited to, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, and/or linolenic acid. The fatty acid supplement disclosed herein may comprise saturated fatty acids, unsaturated fatty acids, monounsaturated fatty acids, and/or polyunsaturated fatty acids. In some embodiments, the fatty acid supplement may comprise a hydrogenated oil. Fatty acid supplements may comprise one or more fatty acid(s). Actual dosage levels and administration regimen of the fatty acid supplement disclosed herein may be varied so as to obtain an amount of fatty acid supplement that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- In further embodiments, the present invention provides methods relating to:
-
- improving fertility;
- treating or preventing infertility;
- inducing ovulation;
- increasing sperm count; or
- increasing lactation;
comprising administering to the subject Compound 4 prepared by the synthetic methods disclosed herein.
- In certain embodiments, such a method of treatment further comprises administering pterostilbene.
- In some embodiments, improving fertility or treating and/or preventing infertility comprises inducing ovulation and/or oocyte and follicle maturation in a female subject. In some embodiments, improving fertility or treating and/or preventing infertility comprising increasing sperm count and/or sperm motility in a male subject.
- In some embodiments, the subject is a mammal (e.g., a human, a non-human mammal). The subject may be male or female. In some embodiments, the subject has impaired fertility (e.g., reduced sperm count, reduced sperm motility, reduced ovulation, reduced follicle and/or oocyte maturation). In some embodiments, the subject is infertile or sterile.
- In some embodiments, provided herein are methods of increasing overall sperm health and/or sperm count in a subject by administering to the subject (e.g., a subject in need thereof) a composition disclosed herein (i.e., a composition comprising nicotinamide riboside (compound 4) and/or pterostilbene). Increasing sperm count may be achieved by increasing the concentration of spermatozoa in seminal fluid, increasing the absolute number of spermatozoa in semen and/or increasing the volume of semen per ejaculate. The methods and compositions disclosed herein may increase overall sperm count by increasing or inducing spermatogenesis. In some embodiments, administering the compositions disclosed herein increase or improve sperm motility (e.g., increasing the percentage of spermatozoa moving in semen or increasing the amount of time spermatozoa are moving) in a subject. In some embodiments, administering the compositions disclosed herein maintains or improves overall sperm health, sperm count, and/or sperm motility in the testes and/or epididymis post spermatogenesis.
- In some embodiments, provided herein are methods of inducing and/or increasing the likelihood of ovulation in a subject by administering to the subject (e.g., a subject in need thereof) a composition disclosed herein (i.e., a composition comprising nicotinamide riboside (compound 4) and/or pterostilbene). In some embodiments, provided herein are methods of inducing follicle and oocyte maturation (e.g., folliculogenesis) in a subject by administering to the subject (e.g., a subject in need thereof) a composition disclosed herein (i.e., a composition comprising nicotinamide riboside (compound 4) and/or pterostilbene).
- Disclosed herein are compositions and methods to aid in in vitro fertilization procedures and practices. In some aspects, provide herein are methods of treating, preserving, or improving gamete (i.e., sperm and/or oocyte) likelihood of fertilization in an in vitro procedure. In some embodiments, compositions disclosed herein are added to semen (e.g., semen obtained from a donor subject) in preparation of for artificial insemination or intrauterine insemination (IUI). In some embodiments, compositions disclosed herein are added to semen in preparation intracytoplasic sperm injection into an oocyte.
- In some embodiments, the compositions disclosed herein may be used to enhance mitochondrial numbers, mitochondrial activity, cellular energy levels or cellular energy-producing potential in oocytes, postnatal female germline stem cells (also referred to herein as OSCs) and/or preimplantation embryos prior to conducting and/or following methods of in vitro fertilization. It has been recently discovered that adult female mammals retain rare germline or oogonial stem cells (OSCs) that routinely produce new oocytes in a manner analogous to germline stem cell support of sperm production in the adult testis, and these OSCs may be new targets for in vitro fertilization therapies (Spradling, Nature 2004 428:133-134). In some embodiments, provided herein are methods of increasing the overall viability of an oocyte removed from a subject (e.g., an oocyte removed in preparation for in vitro fertilization). In some embodiments, an oocyte is treated or stored with a composition disclosed herein prior to in vitro fertilization. In one example, provided herein are methods of in vitro fertilization, the method involving the steps of: incubating an oocyte from a subject with a composition disclosed herein; and fertilizing the oocyte in vitro to form a zygote. In another example, the methods provided herein include a method of in vitro fertilization, the method involving the steps of (a) incubating an OSC from a subject with composition disclosed herein; (b) obtaining a composition containing OSC mitochondria from the OSC; (c) transferring the composition into an isolated oocyte (e.g., an oocyte extracted from a subject); and (d) fertilizing the oocyte in vitro to form a zygote.
- In some embodiments, the composition disclosed herein may be added to a solution used for in vitro fertilization procedures for oocyte preparation and/or storage, such as cell culture medium, oocyte retrieval solution, oocyte washing solution, oocyte in vitro maturation medium, ovarian follicle in vitro maturation medium, oocyte in vitro fertilization medium, embryo culture medium, cleavage medium, vitrification solution, cryopreservation solution and/or embryo thawing medium.
- Gametes may be stored for any period of time with the compositions disclosed herein before in vitro fertilization is performed.
- In some aspects, provided herein are methods of increasing lactation in a subject by administering to the subject (e.g., a subject in need thereof) a composition disclosed herein (i.e., a composition comprising nicotinamide riboside (compound 4) and/or pterostilbene). In some embodiments, increasing lactation comprising increasing the rate at which milk is secreted and/or produced from the mammary glands of a subject. In some embodiments, increasing lactation comprises increasing the volume of secreted milk in the subject. In some embodiments, the subject is a human. In some embodiments the subject is a non-human animal, such as a dairy animal (e.g., a cow, a buffalo, a goat, a sheep, a camel).
- In some aspects, provided herein are methods of improving animal fecundity and/or breeding outcomes in animal husbandry by administering the compositions disclosed herein to a subject(s) (e.g., a non-human subject). In some embodiments, increasing litter size in a subject (e.g., a non-human subject, such as a domesticated animal). In some embodiments, the subject is a mammal. The subject may be a rodent, lagomorph, feline, canine, porcine, ovine, bovine, equine, or primate. For example, a composition disclosed herein may be administered to a female subject to increase number of offspring per litter or reproductive cycle. Alternately, the compositions disclosed herein may be administered to male subjects to increase spermatozoa production to obtain semen samples with increased virility for use in artificial insemination.
- Actual dosage levels and administration regimen of the compositions disclosed herein may be varied so as to obtain an amount of nicotinamide riboside and/or pterostilbene that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- In some embodiments, administration of the composition comprises administration of the composition in one or more dose(s). In some embodiments, administration of the composition comprises administration of the composition in one or more, five or more, ten or more, twenty or more, thirty or more, forty or more, fifty or more, one hundred or more, or one thousand or more dose(s). In some embodiments, the dose comprises at least 25 mg, at least 50 mg, at least 75 mg, at least 100 mg, at least 125 mg, at least 150 mg, at least 200 mg, at least 225 mg, at least 250 mg, at least 275 mg, at least 300 mg, at least 325 mg, at least 350 mg, at least 375 mg, at least 400 mg, at least 425 mg, at least 450 mg, at least 475 mg, at least 500 mg, at least 550 mg, at least 600 mg, at least 650 mg, at least 700 mg, at least 750 mg, at least 800 mg, or at least 850 mg of nicotinamide riboside (compound 4). In some embodiments, the dose comprises at least 5 mg, at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg, at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least 60 mg, at least 65 mg, at least 70 mg, at least 75 mg, at least 80 mg, at least 90 mg, at least 95 mg, at least 100 mg, at least 110 mg, at least 120 mg, at least 130 mg, at least 140 mg, at least 150 mg, at least 160 mg, least 170 mg, at least 180 mg, at least 190 mg, at least 200 mg, or at least 250 mg of pterostilbene.
- The compositions disclosed herein may be administered over any period of time effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The period of time may be at least 1 day, at least 10 days, at least 20 days, at least 30, days, at least 60 days, at least three months, at least six months, at least a year, at least three years, at least five years, or at least ten years. The dose may be administered when needed, sporadically, or at regular intervals. For example, the dose may be administered monthly, weekly, biweekly, triweekly, once a day, or twice a day.
- In further embodiments, the present invention provides methods relating to:
-
- treating or preventing kidney damage;
- treating or preventing acute kidney injury;
- treating or preventing kidney disease; or increasing blood flow to the kidneys;
comprising administering to the subject Compound 4 prepared by the synthetic methods disclosed herein.
- In certain embodiments, such a method of treatment further comprises administering pterostilbene.
- In certain embodiments, the kidney damage is the result of cancer, decreased blood flood to the kidneys (i.e., ischemia), back up of urine in the kidneys, sepsis, trauma, autoimmune disease, drug-induced toxicity (e.g., non-steroidal anti-inflammatory (NSAID) induced nephrotoxicity), lead poisoning, and/or severe dehydration.
- In some embodiments, the acute kidney injury is the result of decreased blood flow to the kidneys (i.e., ischemic injury). Decreased blood flow to the kidneys may be a result of hypotension, blood loss, severe diarrhea, heat attack, heart failure, deceased heart function, organ failure, drug-induced nephrotoxicity (e.g., NSAID induced nephrotoxicity), allergic reactions, bums, trauma (e.g., blunt trauma), and/or surgery. In some embodiments, the acute kidney injury is the result of cancer (e.g., multiple myeloma), sepsis, vasculitis, interstitial nephritis, scleroderma, tubular necrosis, glomerulonephritis, or thrombotic microangiopathy. In some embodiments, the acute kidney injury is the result of blockage of the urinary tract. Blockage of the urinary tract may be caused by bladder cancer, prostate cancer, cervical cancer, an enlarged prostate, kidney stones, or blood clots in the urine.
- In some embodiments, the chronic kidney disease is the result of an immune system disease (e.g., lupus), long term viral disease (e.g., HIV/AIDS, hepatitis B, or hepatitis C), urinary tract infections, polycystic kidney disease, and/or inflammation of glomeruli.
- As used herein, kidney damage may refer to a medical condition of impaired kidney function in which the kidneys fail to adequately filter metabolic wastes from the blood. In some embodiments, kidney damage is also indicative of kidney failure. Examples of conditions that may cause kidney damage include, but are not limited to decreased blood flood to the kidneys, back up of urine in the kidneys, sepsis, trauma (e.g., such as blunt trauma), an autoimmune disease, drug-induced nephrotoxicity (e.g., NSIAD induced nephrotoxicity), heavy mental poisoning (e.g., lead poisoning), or severe dehydration.
- In some aspects, provided herein are methods of treating or preventing acute kidney injury (i.e., in a subject in need thereof). In some embodiments, acute kidney injury is an episode of kidney failure or kidney damage that happens within a few hours or a few days. Acute kidney injury, as used herein, may be characterized by abrupt deterioration in kidney function. In some embodiments, the subject has acute kidney injury, and the acute kidney injury may manifest by an increase in serum creatinine level with or without reduced urine output. In some embodiments, the subject has increased serum creatinine levels. In some embodiments, the subject may have reduced urine output. In some embodiments, the subject has acute kidney injury, and the acute kidney injury may be prerenal (e.g., caused by decreased renal blood flow), intrinsic renal (e.g., caused by a process within the kidneys), or postrenal (e.g., caused by inadequate drainage of urine distal to the kidneys).
- Acute kidney injury or kidney damage may be a result of use (e.g., overuse) of medications, such as NSAIDs, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, cyclosporine, diuretics, tacrolimus, penicillin analogues, cephalosporins, sulfonamides, ciprofloxacin, acyclovir, rifampin, phenytoin, interferon, or proton pump inhibitors. Other causes of acute kidney injury and kidney damage include cardiorenal syndrome, hepatorenal syndrome, abdominal compartment syndrome, hypercalcemia, sepsis, neurogenic shock, infections of the renal parenchyma, glomerulonephritis, viral infections (such as Epstein-Barr virus infections or cytomegalovirus infections), bacterial infections (e.g., bacterial infections caused by bacteria of the Streptococcus or Legionella species), or fungal infections (e.g., fungal infections caused by candidiasis or histoplasmosis). In some embodiments, the acute renal injury and/or kidney damage is caused by a systemic disease, such as sarcoidosis or lupus.
- Additional examples of conditions that cause acute kidney injury and kidney damage include cancer (e.g., multiple myeloma), prolonged hypotension, renal vein thrombosis, malignant hypertension, scleroderma renal crisis, renal atheroembolic disease, renal infarction vasculitis, interstitial nephritis, scleroderma, and or conditions that cause inflammation of or damage to the kidney tubules, such as tubular necrosis, glomerulonephritis, or thrombotic microangiopathy.
- In some embodiments, the acute kidney injury and/or kidney damage is caused by a decrease in blood flow to the kidney. Conditions that may cause a decrease in blood flow to the kidneys includes, for example, blood loss, severe diarrhea, heat attack, heart failure, deceased heart function, organ failure, allergic reactions, bums, and/or trauma. In some embodiments, the subject has undergone surgery, and the subject's blood vessels have been clamped, leading to a decrease of blood flow to the kidneys. In some embodiments, the acute kidney injury or kidney damage is the result of a blockage of the urinary tract. A blockage of the urinary tract may be the result of, for example, neurogenic bladder, retroperitoneal fibrosis, bladder cancer, prostate cancer, cervical cancer, an enlarged prostate, kidney stones, blood clots, or tumors.
- In some embodiments, the subject has a kidney disease. A kidney disease is any condition that affects the kidney's ability to filter compounds out of blood, filter extra water out of blood, and/or help control blood pressure. Kidney disease may be caused by diabetes, hypertension, a systemic disease (e.g., lupus), viral disease (e.g., HIV/AIDS, hepatitis B, or hepatitis C), urinary tract infections, a genetic disease, such as polycystic kidney disease, or any condition that results in the inflammation of kidney glomeruli.
- In some embodiments, the subject's kidney function may be measured prior, during or after administration of a composition disclosed herein. Kidney function may be evaluated as a function of glomerular filtration rate, urine output, or the level of other biomedical markers of kidney health, such as creatinine, urea, nitrogen, phosphorus, or potassium. Markers such as creatinine, urea, nitrogen, phosphorus, or potassium may be measured in the urine or through a blood test.
- Actual dosage levels and administration regimen of the compositions disclosed herein may be varied so as to obtain an amount of nicotinamide riboside (compound 4) and/or pterostilbene that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- In some embodiments, administration of the composition comprises administration of the composition in one or more dose(s). In some embodiments, administration of the composition comprises administration of the composition in one or more, five or more, ten or more, twenty or more, thirty or more, forty or more, fifty or more, one hundred or more, or one thousand or more dose(s). In some embodiments, the dose comprises at least 25 mg, at least 50 mg, at least 75 mg, at least 100 mg, at least 125 mg, at least 150 mg, at least 200 mg, at least 225 mg, at least 250 mg, at least 275 mg, at least 300 mg, at least 325 mg, at least 350 mg, at least 375 mg, at least 400 mg, at least 425 mg, at least 450 mg, at least 475 mg, at least 500 mg, at least 550 mg, at least 600 mg, at least 650 mg, at least 700 mg, at least 750 mg, at least 800 mg, or at least 850 mg of nicotinamide riboside (Compound 4). In some embodiments, the dose comprises at least 5 mg, at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg, at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least 60 mg, at least 65 mg, at least 70 mg, at least 75 mg, at least 80 mg, at least 90 mg, at least 95 mg, at least 100 mg, at least 110 mg, at least 120 mg, at least 130 mg, at least 140 mg, at least 150 mg, at least 160 mg, least 170 mg, at least 180 mg, at least 190 mg, at least 200 mg, or at least 250 mg of pterostilbene.
- The compositions disclosed herein may be administered over any period of time effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The period of time may be at least 1 day, at least 10 days, at least 20 days, at least 30, days, at least 60 days, at least three months, at least six months, at least a year, at least three years, at least five years, or at least ten years. The dose may be administered when needed, sporadically, or at regular intervals. For example, the dose may be administered monthly, weekly, biweekly, triweekly, once a day, or twice a day.
- In further embodiments, the present invention provides methods relating to treating and/or preventing liver related diseases and disorders and for improving liver health in a subject by administering to the subject Compound 4, as prepared by the synthetic methods disclosed herein.
- Specifically, the invention provides a method of:
-
- treating or preventing liver damage;
- treating or preventing fatty liver;
- decreasing the serum level of alanine transaminase (ALT); or
- decreasing the serum level of aspartate transaminase (AST) in a subject;
- comprising administering to the subject Compound 4 prepared by the synthetic methods disclosed herein.
- In certain embodiments, such a method of treatment further comprises administering pterostilbene.
- In certain embodiments, the liver damage is the result of cancer (e.g., liver cancer, bile duct cancer and/or a liver adenoma), cirrhosis, viral infection (e.g., hepatitis A infection, a hepatitis B infection and/or a hepatitis E infection), congenital disorders of metabolism, trauma, autoimmune disease (e.g., autoimmune hepatitis, primary biliary cirrhosis, or primary sclerosing cholangitis), hemochromatosis, hyperoxaluria, oxalosis, Wilson's disease and/or drug-induced hepatotoxicity (e.g., alcohol-induced hepatotoxicity and/or acetaminophen-induced hepatotoxicity). Provided herein are methods of preventing or treating liver damage and/or fatty liver in a subject by administering to the subject (e.g., a subject in need thereof) a composition disclosed herein (i.e., a composition comprising nicotinamide riboside and/or pterostilbene).
- In some embodiments, the subject may have or be predisposed to liver damage and/or fatty liver. Liver damage may result from any condition that causes the cells of the liver (i.e., hepatocytes) to die or otherwise not function normally. Examples of conditions that may cause liver damage include, but are not limited to, cancer (e.g., liver cancer, bile duct cancer, or a liver adenoma), trauma, congenital metabolic disorders (e.g., genetic metabolic disorders resulting in an enzyme deficiency), vascular injury, cirrhosis, a viral infection (e.g., hepatitis A, hepatitis B, hepatitis E), an autoimmune disease (e.g., autoimmune hepatitis, primary biliary cirrhosis, or primary sclerosing cholangitis), hemochromatosis, hyperoxaluria, oxalosis, Wilson's disease, or drug-induced hepatotoxicity (e.g., alcohol-induced hepatotoxicity or acetarninophen-induced hepatotoxicity). Fatty liver may be caused by any condition that causes fat accumulation of liver. These conditions may be, but are not limited to, non-alcoholic fatty liver disease or alcoholic liver disease.
- Disclosed herein are methods of treating or preventing age-related symptoms or diseases comprising administering a composition disclosed herein. Provided herein are methods of decreasing the amount of alanine transaminase (ALT) and/or aspartate transaminase (AST) in a subject comprising administering to the subject a composition provided herein. AST and ALT are reasonably sensitive indicators of liver damage or injury frorn different types of diseases or conditions, and they are often measured in liver tests or liver blood tests. Elevated levels of AST and ALT are associated with liver damage and liver malfunction. In some embodiments, ALT is decreased in the subject by at least 0.1 U/L, at least 0.2 U/L, at least 0.3 U/L, at least 0.4 U/L, at least 0.5 U/L, at least 0.6 U/L, at least 0.7 U/L, at least 0.8 U/L, at least 0.9 U/L, at least 01.0 U/L, 1.1 U/L, at least 1.2 U/L, at least 1.3 U/L, at least 1.4 U/L, at least 1.5 U/L, at least 1.6 U/L, at least 1.7 U/L, at least 1.8 U/L, at least 1.9 U/L, at least 2.0 U/L, 2.1 U/L, at least 2.2 U/L, at least 2.3 U/L, at least 2.4 U/L, at least 2.5 U/L, at least 2.6 U/L, at least 2.7 U/L, at least 2.8 U/L, at least 2.9 U/L, at least 3.0 U/L, at least 3.5 U/L, 4.0 U/L, at least 4.5 U/L, or at least 5.0 U/L after administration of the composition. In some embodiments, the ALT is decreased by at least 0.1 U/L, at least 0.2 U/L, at least 0.3 U/L, at least 0.4 U/L, at least 0.5 U/L, at least 0.6 U/L, at least 0.7 U/L, at least 0.8 U/L, at least 0.9 U/L, at least 01.0 U/L, 1.1 U/L, at least 1.2 U/L, at least 1.3 U/L, at least 1.4 U/L, at least 1.5 U/L, at least 1.6 U/L, at least 1.7 U/L, at least 1.8 U/L, at least 1.9 U/L, at least 2.0 U/L, 2.1 U/L, at least 2.2 U/L, at least 2.3 U/L, at least 2.4 U/L, at least 2.5 U/L, at least 2.6 U/L, at least 2.7 U/L, at least 2.8 U/L, at least 2.9 U/L, at least 3.0 U/L, at least 3.5 U/L, 4.0 U/L, at least 4.5 U/L, or at least 5.0 U/L after administration of the composition.
- Nicotinamide adenine dinucleotide (NAD+) is a coenzyme that participates in many metabolic reactions. NAD+ plays an important role in transcription regulation, longevity, and age-associated diseases. NAD+ levels decrease with age, while increased NAD+ levels are associated with robust health. In some embodiments, provided herein are methods of increasing the amount of NAD+ of a subject by administering a composition disclosed herein. NAD+ may increase by at least 1.0 μg/mL, at least 2.0 μg/mL, at least 3.0 μg/mL, at least 4.0 μg/mL, at least 5.0 μg/mL, at least 6.0 μg/mL, at least 7.0 μg/mL, at least 8.0 μg/mL, at least 9.0 μg/mL, at least 10.0 μg/mL, at least 11.0 μg/mL, at least 12.0 μg/mL, at least 13.0 μg/mL, at least 14.0 μg/mL, at least 15.0 μg/mL, at least 16 μg/mL, at least 17 μg/mL, at least 18 μg/mL, at least 19 μg/mL, at least 20 μg/mL, at least 21 μg/mL, at least 22 μg/mL, at least 23 μg/mL, at least 24 μg/mL, at least 25 μg/mL, at least 26 μg/mL, at least 27 μg/mL, at least 28 μg/mL, at least 29 μg/mL, or at least 30 μg/mL after administration of the composition.
- Provided herein are methods of decreasing blood pressure (e.g., diastolic blood pressure) of a subject by administering a composition herein. In some embodiments, the subject's diastolic blood pressure decreases by at least 1 mmHg, at least 1.5 mmHg, at least 2 mmHg, at least 2.5 mmHg, at least 3 mmHg, at least 3.5 mmHg, at least 4.0 mmHg, at least 4.5 mmHg, or at least 5 mmHg after administration of the composition.
- In certain embodiments, the invention also provides a method of treating a disease comprising administering to a subject compound 4 and/or pterostilbene.
- In certain such embodiments, the disease is a neurodegenerative disease. Exemplary neurodegenerative diseases include Alzheimer's, Parkinson's, and Huntington's Disease.
- In alternative such embodiments, the disease is a skin disorder. Skin disorders may be caused by exposure to the sun; exemplary such disorders are selected from the group consisting of actinic keratoses, lentigines or age spots, seborrheic keratoses, sun burn, photosensitivity, moles, polymorphous light eruption, solar elastosis or wrinkles, skin cancer (such as melanoma, squamous cell carcinoma, and basal cell carcinoma), and freckles. Skin disorders may also be caused by inflammation; exemplary such disorders are selected from the group consisting of psoriasis, contact dermatitis, atopic dermatitis, seborrheic dermatitis, asteatotic eczema, discoid eczema, hand eczema, gravitational/varicose eczema, eczematous drug eruptions, lichen simplex, acne, lichen planus, pityriasis lichenoides, keratosis lichenoides chronica, lichen nitidus, lichen striatus, mycosis fungoides, erythroderma, erythema multiforme, Stevens-Johnson Syndrome, vasculitis, and toxic epidermal necrolysis. In further embodiments, a skin disorder may be caused by autoimmune disease is selected from the group consisting of pyoderma gangrenosum, systemic lupus erythematosus, eosinophilic fasciitis, scleroderma, pemphigus vulgaris, bullous pemphigoid, alopecia areata, vitiligo, psoriasis, dermatomyositis, and dystrophic epidermolysis bullosa.
- In yet alternative embodiments, the disease is obesity or diabetes. The methods may also enable lipid lowering and blood pressure reduction.
- In further alternative embodiments, the disease is muscle wasting or sarcopenia.
- In further alternative embodiments, the disease is an autoimmune disease such as arthritis or lupus.
- In further alternative embodiments, the disease is mitochondrial dysfunction or disease.
- In still further alternative embodiments, the disease is an accelerated aging disease such as progeria.
- In other embodiments, the disease is chemotherapy induced neuropathy, or cognitive decline. The methods may also enable pain reduction.
- In yet further embodiments, the disease is a cancer such as breast cancer, colon cancer, etc.
- In other embodiments, the invention provides methods that promote sirtuin activation, NAD+ boosting, PARP activation, autophagy and mitophagy, or mitochondrial biogenesis.
- In still further embodiments, the invention provides methods of promoting wellness comprising administering to a subject compound 4 and/or pterostilbene.
- In some embodiments, the methods promote wellness by promoting stem cell health and function; such stem cells may be intestinal, skin, muscle, hematopoietic, or neural stem cells.
- The methods may also promote wellness by preventing hearing loss or hair loss.
- Alternatives, the methods may promote healthy hair and nail growth.
- In yet further alternative embodiments, the methods may promote muscle building for endurance and strength, weight loss, or and increased immune response (innate and adaptive function).
- Actual dosage levels and administration regimen of the compositions disclosed herein may be varied so as to obtain an amount of nicotinamide riboside (compound 4) and/or pterostilbene that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.
- In some embodiments, administration of the composition comprises administration of the composition in one or more dose(s). In some embodiments, administration of the composition comprises administration of the composition in one or more, five or more, ten or more, twenty or more, thirty or more, forty or more, fifty or more, one hundred or more, or one thousand or more dose(s). In some embodiments, the dose comprises at least 25 mg, at least 50 mg, at least 75 mg, at least 100 mg, at least 125 mg, at least 150 mg, at least 200 mg, at least 225 mg, at least 250 mg, at least 275 mg, at least 300 mg, at least 325 mg, at least 350 mg, at least 375 mg, at least 400 mg, at least 425 mg, at least 450 mg, at least 475 mg, at least 500 mg, at least 550 mg, at least 600 mg, at least 650 mg, at least 700 mg, at least 750 mg, at least 800 mg, or at least 850 mg of nicotinamide riboside (compound 4). In some embodiments, the dose comprises at least 5 mg, at least 10 mg, at least 15 mg, at least 20 mg, at least 25 mg, at least 30 mg, at least 35 mg, at least 40 mg, at least 45 mg, at least 50 mg, at least 55 mg, at least 60 mg, at least 65 mg, at least 70 mg, at least 75 mg, at least 80 mg, at least 90 mg, at least 95 mg, at least 100 mg, at least 110 mg, at least 120 mg, at least 130 mg, at least 140 mg, at least 150 mg, at least 160 mg, least 170 mg, at least 180 mg, at least 190 mg, at least 200 mg, or at least 250 mg of pterostilbene.
- The compositions disclosed herein may be administered over any period of time effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The period of time may be at least 1 day, at least 10 days, at least 20 days, at least 30, days, at least 60 days, at least three months, at least six months, at least a year, at least three years, at least five years, or at least ten years. The dose may be administered when needed, sporadically, or at regular intervals. For example, the dose may be administered monthly, weekly, biweekly, triweekly, once a day, or twice a day.
- In any of the treatment methods described herein, compound 4, alone or in combination with pterostilbene, may be formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents. In another aspect, the agents described herein can be administered as such, or administered in mixtures with pharmaceutically acceptable carriers and can also be administered in conjunction with other agents. Conjunctive therapy thus includes sequential, simultaneous and separate, or co-administration of one or more compounds of the invention, wherein the therapeutic effects of the first administered has not entirely disappeared when the subsequent compound is administered.
- Compositions useful for the methods of the invention are described above.
- The invention described generally herein will be more readily understood by reference to the following examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.
- A panel of experiments was conducted wherein ribofuranose tetraacetate (compound 1) was treated with a chlorinating agent to form compound 2, followed by treatment with nicotinamide to form compound 3. Results of the panel are summarized in the table below.
-
Weight (g) Volume (mL) mol equivalents Experiment 1A Ribofuranose tetraacetate 20.0 HCl 4.00 Dioxane 2.00 Dichloromethane 100 5.00 Nicotinamide 1.00 Acetonitrile 100 6.00 Procedure: HCl in dioxane was added to ribofuranose tetraacetate in DCM for 12 hours at 25-30° C. Crude was isolated and dissolved in acetonitrile. Nicotinamide was added and stirred for 16 hours at 25-30° C. Added tributylamine and stirred for 30 minutes then rinsed with acetone. Off-white product was formed with 52% yield. Experiment 1B Ribofuranose tetraacetate 20.0 HCl 4.00 Dioxane 2.00 Acetyl chloride Dichloromethane 100 5.00 Nicotinamide 1.00 Acetonitrile 100 6.00 Procedure: HCl in dioxane was added to ribofuranose tetraacetate in DCM for 12 hours at 25-30° C. Crude was isolated and dissolved in acetonitrile. Nicotinamide was added and stirred for 16 hours at 25-30° C. Added tributylamine and stirred for 30 minutes then rinsed with acetone. Off-white product was formed with 54% yield. Experiment 1C Ribofuranose tetraacetate 50.0 0.157 Thionyl chloride 60.0 5.20 Dichloromethane 300 6.00 Acetic acid 25.0 0.500 Nicotinamide 19.1 1.00 Acetonitrile 300 6.00 Tributylamine 10.0 0.200 Procedure: Thionyl chloride was added to ribofuranose tetraacetate and acetic acid in DCM for 16 hours at 25-30° C. Crude was isolated and dissolved in acetonitrile. Nicotinamide was added and stirred for 16 hours at 25-30° C. Reaction was cooled to 0-5° C. and tributylamine was added for 15 minutes and stirred for 30 minutes. Off-white product was formed with 42% yield. Experiment 1D Ribofuranose tetraacetate 100 0.314 HCl 4.00 Dioxane 150 2.00 Dichloromethane 600 6.00 Nicotinamide 42.2 1.10 Acetonitrile 600 6.00 Procedure: HCl in dioxane was added to ribofuranose tetraacetate in DCM for 12 hours at 25-30° C. Crude was isolated and dissolved in acetonitrile. Nicotinamide was added and stirred for 16 hours at 25-30° C. Experiment 1E Ribofuranose tetraacetate 200 0.628 HCl 4.00 Dioxane 393 2.50 Acetyl chloride 22.5 0.500 Dichloromethane 1000 6.00 Nicotinamide 84.6 1.10 Acetonitrile 1200 6.00 Procedure: HCl in dioxane was added to ribofuranose tetraacetate in DCM for 12 hours at 25-30° C. Crude was isolated and dissolved in acetonitrile. Nicotinamide was added and stirred for 16 hours at 25-30° C. Reaction was cooled to 0-5° C. and tributylamine was added stirred for 30 minutes then rinsed with acetonitrile and acetone. Product was formed with 59% yield. Experiment 1F Ribofuranose tetraacetate 500 1.57 HCl 4.00 Dioxane 1570 4.00 Dichloromethane 3000 6.00 Nicotinamide 192 1.00 Acetonitrile 3000 6.00 Tributylamine 100 0.200 Procedure: HCl in dioxane was added to ribofuranose tetraacetate in DCM for 16 hours at 25-30° C. Crude was isolated and dissolved in acetonitrile. Nicotinamide was added and stirred for 16 hours at 25-30° C. Reaction was cooled to 0-5° C. and tributylamine was added stirred for 30 minutes then rinsed with acetonitrile and acetone. Product was formed with 51% yield. Experiment 1G Ribofuranose tetraacetate 4000 HCl 4.00 Dioxane 8000 2.00 Dichloromethane 14000 3.50 Acetyl chloride 400 0.100 Nicotinamide 1690 0.420 Acetonitrile 14000 3.50 Tributylamine 800 0.200 Procedure: HCl in dioxane was added to ribofuranose tetraacetate in DCM and acetyl chloride for 16 hours at 25-30° C. Crude was isolated and dissolved in acetonitrile. Nicotinamide was added and stirred for 16 hours at 25-30° C. Reaction was cooled to 0-5° C. and tributylamine was added stirred for 30 minutes then rinsed with acetonitrile and acetone. Product was formed with 63% yield. Experiment 1H Ribofuranose tetraacetate 1000 3.14 HCl 4.00 Dioxane 3140 4.00 Dichloromethane 6000 6.00 Nicotinamide 384 1.00 Acetonitrile 6000 6.00 Tributylamine 200 0.200 Procedure: HCl in dioxane was added to ribofuranose tetraacetate in DCM for 16 hours at 25-30° C. Crude was isolated and dissolved in acetonitrile. Nicotinamide was added and stirred for 16 hours at 25-30° C. Reaction was cooled to 0-5° C. and tributylamine was added stirred for 30 minutes then rinsed with acetonitrile and acetone. Product was formed with 51% yield. - From the panel of experiments outlined above, the following points were incorporated into the larger scale process of converting compound 1 to compound 3:
- Molar equivalents of nicotinamide are minimized in the range of 1.0 to 1.1 as the nicotinamide hydrochloride (byproduct) is difficult to remove.
- Molar equivalents of HCl are minimized at 1.0 in order to reduce the distillation time. Experiments demonstrated that chloro-intermediate compound 2 is not stable.
- Acetyl chloride can be added as a drying agent.
- Generally, thionyl chloride was less reactive as compared to HCl and has the disadvantage of generating sulfur containing byproducts.
- 246 kg of 4M HCl in dioxane was added to 294 kg of ribofuranose tetraacetate in 471 kg of acetonitrile and stirred for 16 hours at 10-20° C. A sample for reaction completion was taken with a specification of NMT 5% ribofuranose tetraacetate. 237 kg of acetonitrile and 127 kg of nicotinamide were added and stirred for 20 hours at 25-30° C. Reaction was cooled to 0-10° C. and 51 kg of tributylamine was added and stirred for 60 minutes. Product was isolated via filtration and rinsed with 177 kg of acetonitrile and then 474 kg of acetone. Product was dried in vacuum at less than 30 in Hg and NMT 40° C. Product was formed with 49% yield.
-
-
Weight (g) Volume (mL) mol equivalents Experiment 3A Nicotinamide riboside triacetate 5.00 0.0120 Methanol 25.0 5.00 3M Methanolic NH3 20.0 5.00 Procedure: Methanolic NH3 is added to nicotinamide riboside triacetate and kept overnight at −15 to −10° C. Mizxture was cooled to −5 to 0° C. and pH adjusted with HCl. Methanol was added to the filtrates and co-distilled. Brownish product was formed with 54% yield. Experiment 3B Nicotinamide riboside triacetate 150 0.360 Methanol 750 5.00 4M Methanolic NH3 360 4.00 Procedure: Methanolic NH3 is added to nicotinamide riboside triacetate and kept overnight at −15 to −10° C. Methanol was added to the crude and co-distilled. Methanol was added (2 vol.) and pH was adjusted to 4-5 with HCl in methanol. The methyl tert butyl ether (MTBE) (1 vol.) was added and stirred for 30 minutes at room temperature. Light brown product was formed with 82% yield. Experiment 3C Nicotinamide riboside triacetate 100 0.240 Methanol 500 5.00 4M Methanolic NH3 240 4.00 Procedure: Methanolic NH3 is added to nicotinamide riboside triacetate and kept overnight at −15 to −10° C. Methanol was added to the crude and co-distilled. Methanol was added (2 vol.) and pH was adjusted with HCl in methanol and stirred for 1 hour at room temperature. Light brown product was formed with 78% yield Experiment 3D Nicotinamide riboside triacetate 100 0.240 Methanol 500 5.00 4M Methanolic NH3 240 4.00 Procedure: Methanolic NH3 was added to nicotinamide riboside triacetate and kept overnight at −15 to −10° C. Methanol was added and pH was adjusted to 4-5 with HCl in methanol at 0-10° C. Methanol was added to the crude and co-distilled twice. Methanol was added (2 vol.) and stirred for 1 hour at room temperature. Light brown product was formed with 78% yield. Experiment 3E Nicotinamide riboside triacetate 100 0.240 Methanol 500 5.00 4M Methanolic NH3 240 4.00 Procedure: Methanolic NH3 was added to nicotinamide riboside triacetate and kept overnight at −15 to −10° C. pH was adjusted to 4-5 with sulfuric acid at 0-10° C. Methanol was added to the crude and co-distilled twice. Methanol was added (2 vol.) and stirred for 1 hour at room temperature. Light brown product was formed with 79% yield. Experiment 3F Nicotinamide riboside triacetate 1000 2.40 Methanol 5000 5.00 7M Methanolic NH3 1700 5.00 Procedure: Methanolic NH3 is added to nicotinamide riboside triacetate and kept for 16 hour at −10 to −5° C. Methanol was added to the crude and co-distilled. Solids were filtered and washed with methanol and acetone. Off white product was formed with 68% yield. - 408 kg of 7M methanolic NH3 was added to 300 kg of nicotinamide riboside triacetate in 891 kg of methanol and stirred for 15 hour at −10 to 0 TC. A sample for reaction completion was taken with a specification of NMT 5% nicotinamide riboside triacetate. Distillation was completed for NLT 15 hours with vacuum at less than 30 in Hg and temperature NMT 20 TC. Distillation continued until at least 300 kg of distillate was collected. Product was isolated via filtration and rinsed with 475 kg of acetone and then 444 kg of MTBE. Product was dried in vacuum at less than 30 in Hg and NMT 40 TC. Product was formed with 55% yield.
-
- 600 g D-Ribofuranose Tetraacetate was charged to a 5L reactor followed by an acetonitrile rinse (942 g) at 22° C. The mixture was agitated and the D-Ribofuranose Tetraacetate dissolved, thereby forming a clear solution. An endotherm to 6.9° C. was observed. The reactor contents were cooled to 0-5° C., then HCl gas (75.6 g, 1.1 equiv) was charged subsurface over 12 hours in −8 g doses every hour. An IPC sample for reaction completion indicated 8.9 A % D-Ribofuranose Tetraacetate (IPC specification: not more than 5 A % Tetraacetate via CAD Detector). Thus, a supplemental charge of HCl gas (65.8 g, 0.96 equiv) was charged over 2 h in 2 doses. A second IPC sample for reaction completion indicated 2.3 A % D-Ribofuranose Tetraacetate. The reactor jacket temperature was adjusted to 15° C.
- Nicotinamide (253.8 g; 1.1 equiv) was charged to the reactor, resulting in a white suspension which exothermed to 26° C. Acetonitrile (474.0 g) was added to the reactor. The reactor contents were adjusted to 15° C. and tributylamine (384.4 g, 1.1 equiv) was charged over not less than 20 min followed by an acetonitrile rinse (57 g). A moderate exotherm was observed (max 24° C.). The reactor contents were adjusted to 25° C. and agitated for 18 h. An IPC sample for reaction completion indicated 38 A % Nicotinamide (IPC specification: not more than 50% Nicotinamide at 260 nm). No change was seen after 31 h.
- a. Nicotinamide Riboside Chloride Triacetate (NR-A) to Anomer Ratio: 70.3%: 29.7%
- b. In situ Yield Analysis of NR-A: 59.8% (469.9 g)
- Prior to filtration, a 100-200 mg aliquot of the slurry was filtered and washed with acetone and analyzed to show 21.9 A % residual nicotinamide (from acetone-insoluble nicotinamide HCl). Accordingly, the product slurry was cooled to 10° C. and a supplemental charge of tributylamine (45.8 g, 0.131 equiv) was added to compensate for the charge of HCl gas (2.1 equiv). The slurry was warmed to 25° C., held for 2 h, the cooled to 0° C. and allowed to stir overnight (13 h). Prior to filtration a 100-200 mg aliquot of the slurry was filtered and washed with acetone and analyzed to show 1.8 A % residual nicotinamide.
- The pale yellow slurry was chilled to 0° C. (0 to 5° C.) and vacuum filtered through centrifuge cloth (20-25 m pore size). Acetone (1200 g or 948 g) was charged to the empty reactor and cooled to 0-1° C. with stirring to mobilize product residue. After complete deliquoring in the filter, the product cake was washed with the chilled acetone. The product was dried under vacuum for 24 h at 40-45° C. to afford NR-A (378.65 g (48.2% yield)) as white chalky solids (2.0 A % Nicotinamide, 97.4 A % NR-A (260 nm), 0.13 A % Anomer). Product was 100 A % via CAD Detector. Moisture Balance: 0.26% wt loss (75° C., 30 min).
-
- A 5 L jacketed reactor was charged with methanol (350 g). NR-A (350 g) was charged to reactor at 22° C. to give a stirred suspension followed by methanol (350 g) rinse. The reactor contents were cooled to below −5 to −3° C. and diethylamine (49.35 g, 0.8 equiv) was charged to the suspension maintaining not more than 1° C. followed by methanol (133 g) rinse. The reaction mixture was stirred at −3° C. for not less than 2 hours and the suspension became a tea colored solution (at plant-scale a polish filtration may be performed). The reaction was left to stir for 19 h at −3° C. An IPC sample taken at 19 h for reaction completion indicated 4.4% monoacetate (IPC specification: not more than 5% monoacetate at 270 nm). After 28 h: 1.5% monoacetate. An aqueous 3N HCl (0.76 equiv) solution was prepared by adding 37% HCl (63.0 g, 0.76 equiv) to water (189 g). The 3N HCl (0.76 equiv) quench solution was added to the reactor maintaining not more than 2° C. (1 h addition). During the 3N HCl addition, precipitation commenced. The mixture was aged at −3° C. to 0° C. for not less than 12 hours.
- The resulting thick pale yellow suspension was vacuum filtered through centrifuge cloth (20-m pore size) at not more than 0-5° C. Ethanol SDA-3C was charged to the reactor (553 g, 700 mL) and cooled to 0-5° C. The contents were used to rinse the product cake. Acetone (549 g, 700 mL) was charged to the reactor and the contents were cooled to below 0° C. The contents were used to rinse the product cake. MTBE (518.0 g, 700 mL) was charged to the reactor and the contents were cooled to below 0° C. The contents were used to rinse the product cake. The product was dried under vacuum for 24 h at 30-40° C. to afford NR-B (126.9 g (52% yield)) as a pale yellow powder (0.3 A % Nicotinamide, 99.7 A % NR-B (270 nm), and 98.7 wt % vs working lab standard. Moisture Balance: 0.56% wt loss (75° C., 30 min). Percent product loss to filtrate: 43.7 g NR-B, 17.9% of theory.
- All publications and patents mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.
- While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.
Claims (25)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/131,058 US20230348521A1 (en) | 2017-06-30 | 2023-04-05 | Methods of synthesizing nicotinamide riboside |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762527382P | 2017-06-30 | 2017-06-30 | |
PCT/US2018/040228 WO2019006262A1 (en) | 2017-06-30 | 2018-06-29 | Methods of synthesizing nicotinamide riboside |
US201916627583A | 2019-12-30 | 2019-12-30 | |
US18/131,058 US20230348521A1 (en) | 2017-06-30 | 2023-04-05 | Methods of synthesizing nicotinamide riboside |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/627,583 Division US11629163B2 (en) | 2017-06-30 | 2018-06-29 | Methods of synthesizing nicotinamide riboside |
PCT/US2018/040228 Division WO2019006262A1 (en) | 2017-06-30 | 2018-06-29 | Methods of synthesizing nicotinamide riboside |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230348521A1 true US20230348521A1 (en) | 2023-11-02 |
Family
ID=64742745
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/627,583 Active 2039-07-21 US11629163B2 (en) | 2017-06-30 | 2018-06-29 | Methods of synthesizing nicotinamide riboside |
US18/131,058 Pending US20230348521A1 (en) | 2017-06-30 | 2023-04-05 | Methods of synthesizing nicotinamide riboside |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/627,583 Active 2039-07-21 US11629163B2 (en) | 2017-06-30 | 2018-06-29 | Methods of synthesizing nicotinamide riboside |
Country Status (5)
Country | Link |
---|---|
US (2) | US11629163B2 (en) |
JP (1) | JP2020526511A (en) |
CN (1) | CN111315867A (en) |
CA (1) | CA3068728A1 (en) |
WO (1) | WO2019006262A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018102426A1 (en) | 2016-11-29 | 2018-06-07 | University Of Iowa Research Foundation | Use of nad precursors for improving maternal health and/or offspring health |
US20180303861A1 (en) * | 2017-04-24 | 2018-10-25 | Eric Marcotulli | Treating and preventing kidney damage |
CN110642897B (en) * | 2019-09-27 | 2021-04-06 | 武汉一若生物材料有限公司 | Preparation method of beta-nicotinamide riboside chloride |
CN111892635A (en) * | 2020-09-04 | 2020-11-06 | 福建康鸿生物科技有限公司 | Novel synthesis method of nicotinamide ribose |
CN112028954B (en) * | 2020-09-14 | 2022-04-29 | 浩宇康宁健康科技(湖北)有限公司 | Preparation method of nicotinamide ribose |
CN112851730B (en) * | 2021-01-08 | 2023-02-21 | 厦门瑞林药业有限公司 | Synthesis method of NMN intermediate NR chloride |
CN113151378B (en) * | 2021-04-13 | 2023-06-06 | 百瑞全球有限公司 | Method for preparing nucleoside, nicotinic acid adenine dinucleotide and nicotinic acid mononucleotide of nicotinic acid or derivative thereof, enzyme composition and application |
EP4320137A1 (en) | 2021-05-04 | 2024-02-14 | Bohan & Co AS. | A process for synthesis of nicotinamide riboside chloride (nrcl) |
CN113621004A (en) * | 2021-09-13 | 2021-11-09 | 八叶草健康产业研究院(厦门)有限公司 | Preparation method of beta-nicotinamide riboside chloride |
WO2023150667A2 (en) * | 2022-02-04 | 2023-08-10 | Elysium Health Inc. | Ribose linkers and conjugates thereof |
WO2023178017A1 (en) * | 2022-03-12 | 2023-09-21 | Elysium Health Inc. | Deacylation of carbohydrate compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1957086T3 (en) | 2005-11-18 | 2018-06-06 | Cornell Res Foundation Inc | NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE |
US20100035354A1 (en) * | 2008-08-06 | 2010-02-11 | Ettore Bigatti | Process for preparing azacytidine intermediate |
GB201313465D0 (en) * | 2013-07-29 | 2013-09-11 | Queens University Of The Belfast | Methods of preparing nicotinamide riboside and derivatives thereof |
EP3149016A1 (en) | 2014-06-02 | 2017-04-05 | Glaxosmithkline Intellectual Property (No. 2) Limited | Preparation and use of crystalline beta-d-nicotinamide riboside |
US10196412B2 (en) * | 2014-12-24 | 2019-02-05 | The Board Of Trustees Of The Leland Stanford Junior University | Probe for imaging PARP-1 activity |
FI3268379T3 (en) | 2015-03-09 | 2023-12-15 | Grace W R & Co | Crystalline form of nicotinamide riboside |
PT3288637T (en) * | 2015-04-28 | 2022-10-11 | Newsouth Innovations Pty Ltd | Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity |
-
2018
- 2018-06-29 CA CA3068728A patent/CA3068728A1/en active Pending
- 2018-06-29 CN CN201880056536.1A patent/CN111315867A/en active Pending
- 2018-06-29 US US16/627,583 patent/US11629163B2/en active Active
- 2018-06-29 JP JP2020500078A patent/JP2020526511A/en active Pending
- 2018-06-29 WO PCT/US2018/040228 patent/WO2019006262A1/en active Application Filing
-
2023
- 2023-04-05 US US18/131,058 patent/US20230348521A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11629163B2 (en) | 2023-04-18 |
JP2020526511A (en) | 2020-08-31 |
CN111315867A (en) | 2020-06-19 |
WO2019006262A1 (en) | 2019-01-03 |
US20200140475A1 (en) | 2020-05-07 |
CA3068728A1 (en) | 2019-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11629163B2 (en) | Methods of synthesizing nicotinamide riboside | |
US20230063175A1 (en) | Crystalline forms of nicotinamide riboside chloride | |
US10189872B2 (en) | Crystalline form of nicotinamide riboside | |
JP6769000B2 (en) | A novel compound of 4'-thionucleoside, its preparation method, its pharmaceutical composition and its use | |
JP7041673B2 (en) | N-Acylethanolamide Derivatives and Their Use | |
US20120053143A1 (en) | Triacetyl-3-hydroxyphenyladenosine and its use for regulating blood fat | |
JP6289659B2 (en) | Pentacyclic triterpene structure-modifying compounds and their preparation and applications | |
US8664245B2 (en) | Fumarate salts of a histamine H3 receptor antagonist | |
CN112174979B (en) | Medicine for treating polycystic ovarian syndrome and preparation method thereof | |
CA3031458A1 (en) | Vortioxetine analogue and use and preparation thereof | |
TWI481611B (en) | Carbocyclic nucleosides and their pharmaceutical use and compositions | |
WO1995018817A1 (en) | Novel adenosine derivatives, preparation methods therefor, and pharmaceutical compositions containing same | |
US11179380B2 (en) | Compounds and compositions for use in treating psoriasis | |
JP2022531570A (en) | How to treat endometriotic pain by using diaminopyrimidine compounds | |
CN107428791B (en) | Crystalline forms of nicotinamide riboside | |
US10844018B2 (en) | Pyridoxine derivative for treatment of epilepsy | |
JPH11505240A (en) | Drugs for weight loss | |
US20210269441A1 (en) | Crystal form as ASK1 inhibitor and preparation method and application thereof | |
US20080299217A1 (en) | Deuterium-enriched bifeprunox | |
CN115073359A (en) | Preparation method of polysubstituted-1, 4,5, 6-tetrahydro-3-pyridinecarboxylic acid ethyl ester | |
JPH08104638A (en) | Agent for suppressing production of il-5 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ELYSIUM HEALTH, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:POLYCARBON INDUSTRIES INC. D/B/A PCI SYNTHESIS;REEL/FRAME:064254/0368 Effective date: 20170717 Owner name: POLYCARBON INDUSTRIES INC. D/B/A PCI SYNTHESIS, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THAMATAM, RAJESH;REEL/FRAME:064254/0366 Effective date: 20170717 Owner name: ELYSIUM HEALTH, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MARCOTULLI, ERIC;ALMINANA, DAN;DELLINGER, RYAN;AND OTHERS;SIGNING DATES FROM 20221213 TO 20230111;REEL/FRAME:064254/0357 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |